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1.1 Background and aim of the work 
A broad range of diseases with an inflammatory component, such as acute lung injury 
(ALI), acute respiratory distress syndrome (ARDS), sepsis, ischemia-reperfusion injury, 
diabetes mellitus or burn edema, shares a pathologically elevated endothelial permeability 
as common clinical picture.1 Still today, drugs that specifically interfere with barrier-
regulating signaling pathways in the endothelium are widely lacking. Therefore, the 
identification of novel pharmacological drug targets is of utmost importance. The 
characterization of possible targets requires quantitative and sensitive techniques to 
monitor barrier properties of endothelial cell monolayers in vitro mimicking physiological 
and pathophysiological conditions. 
The content of my thesis addresses two important aspects of endothelial permeability 
research: (1) The characterization of Inhibitor of apoptosis proteins (IAPs) as new targets 
in endothelial barrier dysfunction and (2) a comparative study of analytical methods to 
assess barrier function of cultured endothelial cells. 
 
(1) Characterization of IAPs as regulators of endothelial hyperpermeability 
IAPs are well-established suppressors of the programmed cell death. As 
overexpression of IAPs frequently occurs in cancer and correlates with tumor 
progression, poor prognosis and resistance mechanisms, they became attractive 
targets for the development of anti-cancer therapeutics.2 Besides their key role in 
apoptosis, IAPs have emerged as important regulators of inflammatory 
processes.3 Recently, we could provide evidence that IAPs are promising anti-
inflammatory drug targets, since IAP inhibition significantly reduced the knee joint 
swelling in a mouse model of antigen-induced arthritis.4 Additionally, we introduced 
IAPs as important regulators of endothelial activation, in particular of the 
interaction of leukocytes and endothelial cells.4 Based on the finding that IAP 
inhibition reduced leukocyte diapedesis, we hypothesized that IAPs might not only 
regulate the expression of adhesion molecules (ICAM-1), but also govern the 
endothelial barrier function. 
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The aims of the first study were: 
 
 
 
 
 
 
 
(2) A comparative study of macromolecular permeability measurement and 
impedance sensing 
For the validation of potential drug targets, the barrier function of cultured 
endothelial cells can be analyzed with distinct in vitro methods.1 Thus, we set up a 
comparative study, in which the properties of the classic measurement of 
macromolecular permeability and the modern real-time cell-impedance sensing 
were characterized after the application of different established endothelial barrier-
modulating agents. 
 
The aims of the second study were: 
 
 
  
 
  
I. to characterize IAP antagonism as novel approach to prevent endothelial 
barrier dysfunction and 
II. to elucidate the role of IAPs in the underlying permeability-regulating cell 
signaling events. 
I. to evaluate impedance sensing as approach for the analysis endothelial 
barrier function and 
II. to decipher the advantages and limitations of impedance sensing and 
macromolecular permeability measurement. 
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1.2 The vascular endothelium 
The endothelium represents the largest “organ” in the human body, with a surface area up 
to 7000 m2, although it is only one cell layer thick.5 It regulates important physiological 
functions, such as tissue homeostasis, hemostasis, the vascular tone, angiogenesis or the 
immune response.6, 7 Endothelial cells show a characteristic polarized structure; they carry 
a polysaccharide seam (termed glycocalyx) on the luminal side and, on the opposite side, 
they are anchored to the basement membrane (termed basal lamina), which consists of 
extracellular matrix (ECM) proteins. A monolayer of closely connected endothelial cells 
outlines the inner surface of all blood vessels. Due to the strategically unique position 
between the blood and the underlying tissue, the endothelium functions as semi-
permeable barrier to plasma fluid, nutrients, leukocytes and molecules. The supply with 
nutrients as well as the elimination of metabolic byproducts is essential for tissue viability 
and organ function. 
Dysregulation of the endothelial barrier function is a hallmark for inflammatory processes. 
As consequence, excessive flux of plasma proteins and fluid across the endothelium 
leads to their accumulation in the extravascular space. The subsequent tissue swelling 
(termed edema) is detrimental to a vital tissue, because oxygen and nutrient supply is 
impaired.8 
1.2.1 The endothelium as anti-inflammatory drug target 
The vascular endothelium represents an interesting drug target system for anti-
inflammatory strategies due to its dynamic barrier properties, which regulate the 
extravasation of both, macromolecules and leukocytes. Conventional anti-inflammatory 
therapeutics, such as glucocorticoids and non-steroidal anti-inflammatory drugs, are not 
always effective and may provoke serious side-effects.9, 10 Although inflammatory 
processes, as for example the regulation of endothelial barrier function, were subject of 
extensive research efforts for years, the precise mechanisms of the inflammatory 
response remain elusive.1, 11 Therefore, the search for new target-oriented approaches 
that counteract endothelial barrier dysfunction is an ongoing need.12 
 
 
1  INTRODUCTION 14 
1.2.2 Regulation of endothelial permeability 
The prevailing model for the transport of plasma proteins and solutes across the 
endothelium describes two different pathways: the transcellular route (mediated by 
vesicles) and the paracellular pathway (through cell-cell contacts).13 Under physiological 
conditions, macromolecules, e.g. plasma proteins, are transported across the endothelial 
barrier in caveolin-1-rich vesicles (termed caveolae).14 In contrast, smaller molecules 
(diameter < 3 nm) permeate through interendothelial junctions (IEJs), structures that 
mediate cell-cell contacts.15 Inflammatory processes, such as the release of inflammatory 
mediators or the extravasation of leukocytes, affect mainly the paracellular transport. 
Typical pro-inflammatory mediators, like e.g. histamine, thrombin or TNFα, which are 
secreted by mast cells, platelets, macrophages or endothelial cells themselves, disrupt the 
organization of IEJs and thus evoke endothelial barrier dysfunction.16, 17  
The endothelial barrier is determined by a fine balance of adhesive forces, represented by 
IEJs, and contractile forces, generated by intracellular actin-myosin interaction 
(Figure 1).16 IEJs are comprised of mainly adherens junctions (AJs) and, to a lesser 
extent, of tight junctions. This makes the integrity of AJs, which consist primarily of the 
homophilic transmembrane protein vascular endothelial (VE)-cadherin, crucial for the 
endothelial barrier function. Disassembly of AJs is induced upon tyrosine phosphorylation 
of VE-cadherin (e.g. at Y731), thus initiating its internalization or degradation.18 
Furthermore, the intracellular domain of VE-cadherin is connected to the actin 
cytoskeleton via catenins (α, β, γ and p120).19 Hence, the remodeling of the actin 
cytoskeleton directly influences junctional integrity. While a cortical actin rim at the cell 
periphery promotes AJs stability, the reorganization into cytosolic, cell-spanning stress 
fibers disrupts AJs.16 The contractile machinery of endothelial cells is driven by a 
mechanochemical interaction of actin and myosin. Activation occurs after phosphorylation 
of the myosin light chain2 (MLC2) (T18/S19) and builds up a centripetal force that retracts 
endothelial cells from each other, leading to the formation of intercellular gaps. All major 
signaling cascades in the regulation of endothelial permeability either promote (i.e. barrier-
disruptive signaling) or inhibit (i.e. barrier-protective signaling) the three key mechanisms 
of endothelial hyperpermeability: the activation of the contractile machinery, the actin 
remodeling and the disruption of IEJs.  
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Figure 1  Regulation of the endothelial barrier. Homophilic VE-cadherin, the most prominent protein of 
IEJs, connects two adjacant endothelial cells, which are embeded in the extracellular matrix. Regulatory 
proteins (α-, β-, γ-, p120-catenin) link the intracellular part of VE-cadherin to cytoskeletal actin filaments. 
Cytoskeletal contraction is promoted through activation of myosin. 
 
1.2.3 Barrier-disruptive signaling events 
Typical mediators of the acute inflammatory response, such as thrombin and histamine, 
induce endothelial hyperpermeability via an activation of G-protein coupled receptors. 
Histamine activates the histamine (H)-1 receptor, which causes only a transient increase 
of permeability (5 min), whereas the serine protease thrombin induces a prolonged 
hyperpermeability (1 h) after cleavage and activation of its receptor, the protease-
activated receptor (PAR)-1.20 Alternatively to the serine protease thrombin, the thrombin 
receptor activating peptide (TRAP), mimicking the extracellular cleaved N-terminus of 
PAR, can be used for receptor activation.21, 22 Both the activation of H-1 and PAR-1 lead 
to Ca2+ mobilization, protein kinase C (PKC) activation and mitogen-activated protein 
kinase (MAPK) signaling, whereas the small GTPase RhoA is exclusively activated by 
PAR-1 (Figure 2).23  
VE-Cad.α
actin
filaments
β
γ p120
endothelial cell
extracellular matrix
myosin
1  INTRODUCTION 16 
 
 
Figure 2  Thrombin-induced signaling transduction for endothelial hyperpermeability. Thrombin-
induced PAR-1 cleavage activates MAPKs and elevates cytosolic Ca2+. The subsequent activation of various 
signaling pathways induces stress fiber formation, an activation of the contractile machinery and the 
disassembly of AJs. For details see the following text passages. 
 
1.2.3.1 Cytosolic calcium 
Calcium is a ubiquitous second messenger with a central role in the regulation of 
endothelial permeability. Upon PAR-1 activation, phospholipase Cβ (PLCβ) catalyzes the 
production of inositol triphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 
4,5-bisphosphate (PIP2).15 IP3 evokes an immediate release of Ca2+ from its endoplasmic 
stores, whereas DAG triggers the receptor-operated Ca2+ channel (ROC) influx through 
transient receptor potential channels (TRPC 3/6) from the extracellular compartment.24 
This first wave of Ca2+, activates store-operated Ca2+ channels (SOCs) (TRPC 1/4), which 
further augment intracellular Ca2+ ([Ca2+]i) levels.25 
Free cytosolic Ca2+ binds to calmodulin, which leads to an activation of the myosin light 
chain kinase (MLCK).26 The main biological function of MLCK is the phosphorylation of 
MLC2 at S19 and subsequently at T18.27   
Thrombin
MAPKs PKC MLCK
PAR1
endothelial cell
Ca²⁺
RhoA
MLCP
p-MLC2MLC2
contractionstress fibersAJ disruption
ROCK
ER
?
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1.2.3.2 Protein kinase C 
PKCs are a large family of serine/threonine kinases that are differentially regulated by 
Ca2+, DAG or phospholipids. Despite the minor effects on the basal barrier properties of 
the endothelium, PKCs, especially the classical isoforms (PKC α, β), are described as 
important regulators of induced endothelial hyperpermeability.28, 29 For example, it is 
known that PKC activates MLCK, and furthermore, promotes AJ disassembly.30, 31 
Additionally, PKC can induce RhoA activation through phosphorylation of immediate 
upstream regulators of RhoA.13 
1.2.3.3 Mitogen-activated protein kinases 
While extracellular signal-related kinase (ERK) predominantly controls cell proliferation, 
p38 and c-jun N-terminal kinase (JNK) are involved in the cellular stress response. The 
activation of MAPKs is regulated by an upstream phosphorylation cascade, where multiple 
kinases, as for example PKCs, are involved. Although the molecular mechanisms are not 
completely understood, it is evident that ERK and p38 contribute to the thrombin-induced 
endothelial hyperpermeability.32, 33 Furthermore, it is known that p38 and its downstream 
target HSP27 are critical regulators of stress fiber formation and TNFα-induced 
hyperpermeability.34 Moreover, a role for ERK as activator for MLCK has been 
hypothesized.27 JNK was reported to be crucially involved in microvascular leakage and 
neutrophil accumulation in vivo.35 Thus, also the best studied MAPKs (ERK, JNK and p38) 
are implicated in the permeability regulation.35, 36 
1.2.3.4 RhoA GTPase 
The family of small GTPases acts as molecular switches, cycling between an inactive 
GDP- and an active GTP-loaded state.37 The activation of these GTPases is controlled by 
three different classes of proteins (Figure 3): (1) Guanine exchange factors (GEFs) that 
catalyze the substitution of GDP by GTP, (2) GTPase-activating proteins (GAPs) that 
hydrolyze GTP into GDP and phosphate and (3) guanine nucleotide dissociation inhibitors 
(GDIs) that stabilizes and sequesters inactive RhoA in the cytosol.37 RhoGTPases 
modulate the organization and dynamics of the actin cytoskeleton and, thus they regulate 
endothelial barrier properties.38, 39  
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Figure 3 Regulation of RhoGTPase activity. Small GTPases like RhoA are stabilized in the inactive 
(GDP-bound) conformation by cytosolic RhoGDIs. Upon release from GDI binding, RhoA translocates to the 
plasma membrane, where it is converted to the activated (GTP-bound) form. The activation is promoted by 
GEFs. Inactivation occurs when GTP gets hydrolzed by GAPs. 
 
Activation of RhoA increases endothelial permeability, whereas a certain basal RhoA 
activity is necessary for the physiological barrier function.39 Upon thrombin treatment, 
PKCα either activates the specific p115-RhoGEF or inhibits RhoGDI-1, both leading to 
RhoA activation.13 The subsequently induced cellular contraction, stress fiber formation 
and endothelial permeability are mediated through the activation of the RhoA downstream 
target RhoA kinase (ROCK).40 ROCK inhibits the myosin light chain phosphatase (MLCP) 
by phosphorylation of the inhibitory myosin phosphatase targeting (MYPT) subunit 1.23 
Hence, MLCP inhibition extends and enhances the phosphorylation of MLC2 and, thus, 
acto-myosin-based contraction.  
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GDP
GEF
GTPGDP
GAP
RhoA
GDP
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1.2.4 Barrier-protective signaling events 
A broad variety of substances induces endothelial hyperpermeability, but only few are 
known that possess protective characteristics.12 For example, phospholipids released 
from platelets tighten the endothelial barrier.41 The typical assembly of an actin ring at the 
cell periphery, encompassing the plasma membrane, enhances the endothelial barrier. 
This cortical actin rim stabilizes the cell morphology and strengthens IEJs.42 
1.2.4.1 cAMP 
The second messenger cAMP is the most important signaling molecule that generally 
enhances endothelial barrier function (Figure 4).12 Activation of the adenylyl cyclase 
(e.g. by forskolin) generates cAMP, which is subsequently degraded by 
phosphodiesterases (PDE). Increasing cAMP levels activate protein kinase A (PKA), 
which mediates the dephosphorylation of MLC2, leading to the dissociation of actin from 
myosin.43, 44 More recently, a second mechanism independent of PKA was introduced: 
cAMP triggers the exchange protein directly affected by cAMP (EPAC)1 signaling 
cascade. EPAC1 is a GEF for the Ras-like GTPase Rap1, which induces the formation of 
cortical actin and the stabilization of AJs.45 Interestingly, a recent study demonstrated that 
the RhoGTPase Rac1 is a hub for both the PKA- and the EPAC1-mediated barrier 
protective effects of cAMP.46 
 
 
Figure 4  Signaling pathways of cAMP-dependent barrier stabilization. Upon its activation, the 
adenylyl  cyclase (AC) initiates cAMP synthesis, whereas phosphodiesterases (PDE) degrade cAMP. cAMP 
induce both PKA- and EPAC1-dependent signaling pathways, which converge in Rac1 activation. Rac1 
promotes endothelial barrier protection through the formation of cortical actin. For details see the text passage 
1.2.4.1 and 1.2.4.2. 
endothelial cell
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PKA EPAC1
AJ stabilizationcortical actin
RAP1
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1.2.4.2 Rac1 GTPase 
Even though the activation pattern of Rac1 and RhoA is identical (see 1.2.3.4 RhoA 
GTPase), both small GTPases fulfill antagonistic functions in terms of permeability 
regulation. Rac1 stabilizes the endothelial barrier under resting conditions and protects 
against inflammatory incitement. Rac1 induces a translocation of cortactin to the cell 
periphery, thus promoting a cortical actin assembly.39 Furthermore, the Rac1 downstream 
target p21-activated kinase (PAK) activates LIM kinase (LIMK) 1. LIMK1 phosphorylates 
and inactivates the actin severing molecule cofilin, which further stabilizes cortical actin.47 
Finally, also a crosstalk between Rac1 and RhoA is suggested, as Rac1 activation was 
found to limit RhoA activity.39  
 
1.2.5 Measurement of endothelial permeability 
A variety of methods exist to determine endothelial permeability in vivo and in vitro. 
Quantitative measurements with classic in vivo approaches like the Miles assay,48 where 
a colored dye is injected into the blood circulation, or the intravital microscopic 
measurement of the transvascular flux of labeled-macromolecules49 are labor intensive 
and challenging to perform.1 Complex molecular and pharmacological approaches are 
more easily addressable in cultured endothelial cells that allow a better control of 
experimental conditions. Cultured endothelial monolayers display many physiological 
properties of the endothelial barrier, including the expression of IEJs, a physiological 
electrical resistance, a selective size-dependent passage of macromolecules, endothelial 
polarity and the response to vasoactive agents.20 Two techniques have been considered 
as gold standard throughout the last decades: the measurement of macromolecular 
permeability and the determination of the transendothelial resistance. More recently, C. 
Keese and the Nobel laureate I. Giaever introduced impedance sensing as alternative 
approach.50 
1.2.5.1 Macromolecular permeability measurement 
The transvascular solute flux is simulated with a Transwell® two-compartment in vitro 
model (compare chapter 2.4). Malik and colleagues initially introduced the size-selective 
transport through endothelial pore equivalents (i.e. IEJs) to study endothelial barrier 
function.51 In the absence of convective fluid flow, the permeation across an endothelial 
cell layer depends entirely on diffusive forces.1 A labeled macromolecule is added to the 
upper compartment at a defined concentration, and its appearance in the lower 
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compartment is determined at fixed time points and used for quantification. Endothelial 
cells respond to permeability-inducing agonists, such as thrombin, with an increasing 
passage of macromolecules.52 
1.2.5.2 Transendothelial electrical resistance 
Lipophilic cell membranes function as electrical insulators that maintain the physiological 
membrane potential. Charge carriers (i.e. ions) in aqueous solution cross the endothelium 
through IEJs, which function as biological resistors. The resistance across an endothelial 
cell layer is referred to as transendothelial electrical resistance (TEER) and serves as 
measure for the ionic permeability of intercellular clefts. Changes of the TEER are 
determined according to Ohm’s law by application of a constant direct current. For 
example, the treatment of endothelial cells with inflammatory mediators, like e.g. 
histamine or thrombin, causes a rapid drop of TEER values, which accounts for the 
induced endothelial hyperpermeability.20 
1.2.5.3 Impedance measurement 
Electric cell impedance sensing is a label-free method to study morphologic alterations of 
cultured cells on gold electrodes under real-time conditions. Impedance, also known as 
resistance in alternating currents, is a complex physical quantity consisting of an 
imaginary capacitive (membrane properties) and a real resistive (IEJ integrity) contribution 
(compare chapter 2.6).53 Thus, impedance sensing monitors changes of cellular 
morphology in terms of altered cell-electrode contacts.54 The non-invasive impedance 
measurement offers a variety of applications, such as the investigation of cell growth, 
attachment and spreading, cell motility, in situ electroporation, cytotoxicity of compounds, 
cell differentiation, wound healing and migration or receptor stimulation, which all can be 
monitored in real-time with a temporal resolution ranging from seconds up to weeks.55-62 
Soon after its introduction, impedance measurement was utilized for the assessment of 
the endothelial barrier function.63 The measured impedance is used as indicator for ionic 
permeability, comparable to TEER readings. However, this model is oversimplified as it 
does not account morphological changes that appear independently of IEJs. A profound 
validation of impedance measurement as alternative technique to monitor endothelial 
permeability is still missing to date.  
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1.3 Inhibitor of apoptosis proteins 
As already indicated by their name, inhibitor of apoptosis proteins (IAPs) represent crucial 
regulators of cell death. Today, however, this is only one amongst many different cellular 
functions known for IAPs. They are also involved in cell proliferation, differentiation, cell 
morphogenesis, cell invasion, metastasis, immunity and inflammatory signaling.64, 65 
1.3.1 IAP family 
20 years ago, a gene that inhibits apoptosis in virus-infected Spodoptera frugiperda (engl. 
fall armyworm) cells was discovered and named iap.66 The IAP family members are highly 
conserved in different organisms like yeast, nematodes, flies or higher vertebrates.67 
These proteins are characterized by the presence of a variable number of baculovirus IAP 
repeat (BIR) domains and their anti-apoptotic capacity. Up to date, there are 8 human 
homologues described: NAIP, survivin, livin, ILP-2, apollon, X-chromosomal linked IAP 
(XIAP), cellular IAP1 (cIAP1) and cellular IAP2 (cIAP2). The last three mentioned are the 
best-characterized mammalian representatives, on which we consequently focused on.65 
1.3.2 Structure and function of IAPs 
IAPs were first believed to be functionally restricted to the inhibition of apoptosis due to 
the discovery that the BIR domains bind and inhibit the proteolytic activity of caspases.68 
This view was extend and refined with the structural characterization of the distinct IAP 
domains. 
XIAP, cIAP1 and cIAP2, each contain three N-terminal BIR domains, an ubiquitin-
associated (UBA) domain as well as a really interesting new gene (RING) domain at the 
C-terminus. Both cIAPs additionally bear a caspase recruitment domain (CARD). 
 
 
Figure 5  Structural elements of IAPs. BIR: baculoviral IAP repeat, UBA: ubiquitin-associated, CARD: 
caspase recruitment domain, RING: really interesting new gene. A describtion of the functional features of 
distinct domains is found in the subsequent text passage. 
H₂N COOH XIAP
cIAP 1/2
BIR1 BIR2 BIR3 UBA RING
H₂N COOHBIR1 BIR2 BIR3 UBA RINGCARD
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BIR domains can be divided into type I (BIR1) and II (BIR2, 3) depending on the 
appearance of a deep peptide-binding groove within their sequence. This hydrophobic 
cleft is only found in type II BIR domains and is responsible for the binding of special N-
terminal peptide sequences called IAP-binding motifs (IBMs).3 These IBMs are present in 
second mitochondria-derived activator of caspases (Smac), which is the endogenous IAP 
antagonist, and in caspases-3, -7 and -9.69 Although XIAP, cIAP1 and cIAP2 were shown 
to bind these caspases, XIAP is the only inhibitor of caspases activity.70 Of note, cIAPs 
regulate cell death not directly via caspases, but through inhibition of the ripoptosome. 
The ripoptosome is a recently discovered death-inducing complex, that assembles 
spontaneously upon cIAP depletion.71 Type I BIR is not involved in the binding of 
caspases, but interacts with signaling adapter molecules, such as tumor necrosis factor 
(TNF)-associated factor (TRAF) 1 and 2, that are associated with TNF receptor 
signaling.72 Summing up, BIR domains are versatile protein-protein interaction domains 
with diverse binding partners in apoptotic and signaling processes, despite their structural 
similarity.69 
The RING domain possesses ubiquitin protein ligase (E3) activity. Ubiquitin (Ub) residues 
are transferred to target proteins in conjunction with an Ub activating enzyme (E1) and an 
Ub conjugating enzyme (E2).73 Target selectivity is determined only by the substrate 
recognition through the respective E3 ligase. For example, IAPs, as E3 ligases, promote 
the ubiquitination of various substrates, like e.g. Rac1, caspases, Smac or IAPs 
themselves.74-76 Different linkages of the mono- or poly-Ub residues determine the fate of 
the targeted protein. Recent findings indicate that K6-, K11-, K27-, K29-, K33- and K48-
linked modifications promote proteasomal degradation.77 In contrast, K63-linked and M1-
linked Ub chains have a scaffolding function in the activation of kinases in NFκB 
signaling.78  
The UBA domain binds to poly-Ub residues, thus affecting NFκB signaling.79 Furthermore, 
CARD was recently determined as auto-inhibitory domain to suppress the E3 ligase 
activity of cIAP1.80  
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1.3.3 IAP antagonists 
IAPs are expressed at elevated levels in various solid tumors including esophageal, 
hepatocellular, cervix, liver, lung and pancreatic cancer as well as in diverse 
hematological malignancies.2, 81 Their crucial contribution for tumor cell survival and 
resistance development made IAPs attractive targets in cancer research. The approach to 
neutralize IAPs, led to the development of small molecule antagonists that mimick the 
endogenous IAP inhibitor Smac.81 
Upon proapoptotic stimuli, Smac is liberated from its mitochondrial stores in order to bind 
cytosolic IAPs, which in turn leads to unimpeded caspase activation.82 The first four N-
terminal amino acids of Smac (AVPI), known as most prominent IBM, are essential for the 
binding to the BIR3 domain.83  
Indeed, peptides derived from AVPI were proven to mimic the activity of the Smac protein 
and were consequently used to antagonize IAPs.84 It was subsequently demonstrated that 
IAP antagonists induce apoptosis through degradation of cIAP1, NFκB activation and 
autocrine TNFα production.76, 85 A recent study revealed that IAP antagonists induce a 
conformational change of cIAP1 prompting RING dimerization, thus mediating a rapid 
auto-ubiquitination and subsequent degradation of cIAP1.86 In contrast, XIAP is not 
degraded upon treatment with Smac mimetics.76  
As the therapeutic application of peptides is limited by their proteolytic stability, restricted 
cell permeation and poor pharmacokinetics, synthetic peptidomimetics with improved 
pharmacological properties were designed. Oost et al. used the IBM AVPFY, which binds 
to XIAP with 4-fold higher affinity than AVPI,87 to generate four peptide libraries. Based on 
structure-activity relationship (SAR) studies, they identified a series of proteolytically 
stable, capped tripeptides.88 One of these peptidomimetics, compound 11 (A 4.10099.1, in 
the following referred to as ABT), exhibited a high binding affinity to the XIAP BIR3 
domain (Kd = 16 nM). ABT, depicted in Fig. 6, was used as IAP antagonist in this work.  
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Figure 6 Structure of the IAP antagonist ABT. A 4.10099.1 (ABT) was synthesized and characterized 
in the publication Oost et al.( 2004) as compound 11. 
In general, IAP antagonists have demonstrated good anti-tumor properties in several in 
vivo xenograft models, showing no remarkable toxicity profile.89 Notably, IAP antagonists 
do not induce a sensitization to apoptosis in normal primary cells, nor do they affect highly 
proliferative tissues in mice.2, 90 Currently, there are at least five clinical trials in phase I 
evaluating the potential of small molecule IAP antagonists as cancer therapeutics.2 Since 
IAPs are involved in various physiological processes, as the immune- or the inflammatory 
response, the targeting of IAPs might open up therapeutic strategies in other diseases 
than cancer.91  
 
2 MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 ABT 
The IAP antagonist A-4.10099.1, here referred as ABT, was previously characterized in 
Oost et al..88 It was kindly provided by Abbott Bioresearch Corp. (Worcester, MA, USA). 
The compound was dissolved in DMSO for complete solubilization at a concentration of 
50 mM and stored at -80 °C for further use. 
2.1.2  Smac085 
The dimeric compound Smac085 (unpublished structure) was kindly provided by Prof. 
Pierfausto Seneci (Department of Organic and Industrial Chemistry, University of Milano, 
Italy). The substance was dissolved in DMSO for complete solubilization at a 
concentration of 10 mM and stored at -80 °C for further utilization. 
2.1.3 Biochemicals, inhibitors, cell culture reagents and technical 
equipment 
Table 1  Biochemicals 
Reagent Producer 
Accustain® formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Amaxa™ Nucleofector HUVEC kit Lonza, Cologne, Germany 
BC Assay reagent Interchim, Montulocon, France 
Blebbistatin Sigma-Aldrich, Taufkirchen, Germany 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent Roti®-Quant Carl Roth, Karlsruhe, Germany 
p-Coumaric acid Sigma-Aldrich, Taufkirchen, Germany 
DMSO AppliChem, Darmstadt, Germany 
ECL Plus WB Detection reagent GE Healthcare, Munich, Germany 
FITC-Dextran 40 kDa Sigma-Aldrich, Taufkirchen, Germany 
FluorSave™ Reagent mounting medium Merck, Darmstadt, Germany 
Forskolin Enzo Life Sciences GmbH, Lörrach, 
Germany 
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All other common biochemical substances were purchased from Sigma-Aldrich, 
AppliChem, Carl Roth or Merck. 
 
Table 2  Inhibitors 
Inhibitor Producer 
Aprotinin Sigma-Aldrich, Taufkirchen, Germany 
ß-glycerophosphate Calbiochem, Darmstadt, Germany 
Complete® mini EDTA free Roche diagnostics, Penzberg, Germany 
Leupeptin Sigma-Aldrich, Taufkirchen, Germany 
NaF  Merck, Darmstadt, Germany 
Na3VO4  ICN Biomedicals, Aurora, OH, USA 
Phenylmethylsulfonyl fluoride (PMSF)  Sigma-Aldrich, Taufkirchen, Germany 
 
 
 
 
 
 
Reagent Producer 
FURA-2 AM ester Biotrend, Cologne, Germany 
Glutathione-sepharose Sigma-Aldrich, Taufkirchen, Germany 
Histamine Sigma-Aldrich, Taufkirchen, Germany 
Luminol Sigma-Aldrich, Taufkirchen, Germany 
Page Ruler™ Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Protein A-agarose Sigma-Aldrich, Taufkirchen, Germany 
Protein G-agarose Calbiochem, Darmstadt, Germany 
Protein A/G-sepharose Roche, Mannheim, Germany 
Targefect HUVEC kit Targeting Systems, El Cajon, CA, USA 
Thrombin Sigma-Aldrich, Taufkirchen, Germany 
Thrombin receptor activating peptide 
(TRAP) 
Mo-Bi-Tec, Göttingen, Germany  
Triton X-100 Merck, Darmstadt, Germany 
Tumor necrosis factor-α (TNFα) PeproTech GmbH, Hamburg, Germany 
Tween®20 BDH/Prolabo®, Ismaning, Germany 
Y-27632 (hydrochloride) Cayman Chemical, Ann Arbor, MI, USA 
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Table 3  Cell culture reagents 
 
Table 4 Technical equipment 
Reagent Producer 
Amphotericin B 250 µg/ml AppliChem, Darmstadt, Germany 
Collagen A/G Biochrom AG, Berlin, Germany 
Collagenase A Roche, Mannheim, Germany 
DMEM/High Glucose PAA Laboratories, Pasching, Austria 
Endothelial Cell Growth Medium (ECGM) 
with Supplement Mix  #C-39215 
PromoCell, Heidelberg, Germany 
FCS gold  PAA Laboratories, Pasching, Austria 
M199 Medium PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
Name Device Manufacturer  
Axiovert 200 Inverted microscope Zeiss, Jena, Germany  
Cell culture flasks, plates, 
dishes 
Disposable cell 
culture material 
TPP, Trasadingen, Switzerland  
Curix 60 Tabletop film 
developer 
Agfa, Cologne, Germany  
Ibidi µ-slides Microscopy slides Ibidi GmbH, Munich, Germany  
LSM 510 META Confocal laser 
scanning microscope 
Zeiss, Jena, Germany  
Mikro 22R Table centrifuge Hettich, Tuttlingen, Germany  
Nanodrop® ND-1000 Spectrophotometer Peqlab, Wilmington, DE, USA  
Nucleofactor™ 2 Transfection device Lonza, GmbH, Cologne, 
Germany 
 
Odyssey 2.1 Infrared Imaging 
System 
Li-COR Biosciences, Lincoln, 
NE, USA 
 
Protein electrophoresis 
and blotting equipment 
Unit, power supplies Bio-rad, Munich, Germany  
SpectraFluor™ Microplate 
multifunction reader 
Tecan, Männedorf, Switzerland  
Sunrise™ Microplate 
absorbance reader 
Tecan, Männedorf, Switzerland  
Custom-built TEER reader Transendothelial 
resistance reader 
Prof. Dr. W. Nagel, Munich, 
Germany 
 
Transwell® plate (0.4 µm, 
Ø 12 mm, PET) 
Two-compartment 
permeability assay 
Corning, New York, USA  
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2.2 Cell culture 
2.2.1 Cell culture solutions and reagents 
The following solutions were used for the isolation and cultivation of endothelial cells.  
Table 5  Cell culture buffers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Device Manufacturer  
Vi-Cell™ XR Cell counter Beckman Coulter, Fullerton, 
CA, USA 
 
xCELLigence™ DP Real-Time Cell 
Analyzer 
Roche Diagnostics, Mannheim, 
Germany 
 
PBS (pH 7.4) 
NaCl  132.2 mM 
Na2HPO4 10.4 mM 
KH2PO4 3.2 mM 
H2O  
PBS+ Ca2+/Mg2+ (pH 7.4) 
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 8.1 mM 
KH2PO4 1.5 mM 
CaCl2 0.7 mM 
MgCl2 0.5 mM 
H2O  
HEPES (pH 7.4) 
NaCl  125 mM 
KCl 3 mM 
NaH2PO4 1.25 mM 
CaCl2 2.5 mM 
MgCl2 1.5 mM 
Glucose 10 mM 
HEPES 10 mM 
H2O  
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Table 6  Cell culture solutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annotation: FCS gold (fetal calves serum) was partially thawed for 30 min at room 
temperature, and subsequently fully thawed at 37 °C. For heat inactivation it was kept at 
56 °C for 30 min. Aliquots of FCS were stored at -20 °C. 
2.2.2 Endothelial cells 
Endothelial cells (ECs) were cultured in an incubator (Heraeus, Hanau, Germany) at 
37 °C with 5 % CO2. Routine tests for mycoplasma contamination were performed with the 
PCR detection kit Venor®GeM (Minerva Biolabs, Berlin, Germany). All utilized cell culture 
flasks, dishes and multiwell-plates were coated before use with Collagen G at least 
20 min.  
2.2.2.1 HMEC-1 (Human dermal microvascular endothelial cells) 
The cell line CDC/EU.HMEC-1 was kindly provided by the Centers for Disease Control 
and Prevention (Atlanta, GA, USA). The immortalized HMEC-1 cell line was developed by 
transfecting human dermal microvascular endothelial cells with a plasmid coding for the 
Endothelial Cell Growth Medium 
ECGM  500 ml 
Supplement Mix #C-
39215 
23.5 ml 
FCS gold 50 ml 
Amphothericin B  
(250 µg/ml) 
5 ml  
Penicillin (10,000 U/ml)/ 
Streptomycin (10 mg/ml) 
5 ml 
Stopping medium 
M 199 Medium 500 ml 
FCS gold 50 ml 
DMEM/High Glucose 
DMEM 500 ml 
glucose 4.5 g/ml 
Freezing medium  
FCS gold 50 % 
DMSO 8 % 
ECGM  
Collagen G  
Collagen G 0.001 % 
PBS  
Trypsin/EDTA (T/E)  
Trypsin 0.05 % 
EDTA 0.20 % 
PBS  
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transforming SV40 large T-antigen. HMECs maintain endothelial morphology, phenotype, 
and functional characteristics.92, 93 HMECs were exclusively used for macromolecular 
permeability assays and impedance measurement. 
2.2.2.2 HUVECs (Human umbilical vein endothelial cells) 
Human umbilical cords were kindly provided by Klinikum München Pasing, Frauenklinik 
München West/Krüsmannklinik, Rotkreuzklinikum München and Wolfart Klinik Gräfelfing. 
Immediately after childbirth, umbilical cords were stored in PBS+ Ca2+/Mg2+ containing 
penicillin (100 U/ml)/streptomycin (100 μg/ml) at 4 °C. HUVECs were freshly isolated 
every week. The umbilical veins were washed with PBS+ Ca2+/Mg2+, filled with 0.1 g/l 
collagenase A, and incubated for 45 min at 37 °C. To extract endothelial cells, the veins 
were flushed with stopping medium and the cell suspension was centrifuged (1,000 rpm, 
5 min). Then, HUVECs were resuspended and carefully vortexed in growth medium and 
plated in a 25 cm2 flask (passage #0). After reaching confluency, cells were trypsinized 
and plated in a 75 cm2 flask (passage #1). Cells were used until passage #3 for 
experiments. 
2.2.3 Passaging 
Confluent cells were either sub-cultured 1:3 in 75 cm2 culture flasks or plated for 
experiments in multiwell-plates, dishes or ibidi µ-slides. For passaging, growth medium 
was removed; cells were washed twice with PBS and were afterwards incubated with 
trypsin/EDTA (T/E) for 1-2 min at 37 °C. The detached cells were collected in stopping 
medium, which terminated the enzymatic reaction. After centrifugation (1,000 rpm, 5 min, 
room temperature), the pellet was resuspended in growth medium and cells were plated. 
2.2.4 Freezing and thawing 
Before freezing, confluent HMECs cultured in a 75 cm2 flask were trypsinized, centrifuged 
(1,000 rpm, 5 min, room temperature) and resuspended in 3 ml ice-cold freezing medium. 
1.5 ml aliquots were frozen in cryovials. After an initial storage at -80 °C for 24 h, aliquots 
were transferred into liquid nitrogen tanks for long-term storage.  
For thawing of cells, a cryovial was heated to 37 °C and the content was immediately 
mixed with growth medium at 37 °C. Before seeding in a 75 cm2 culture flask, the DMSO-
containing freezing medium was removed by centrifugation and resuspension in growth 
medium. 
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2.3 Western blot analysis 
2.3.1 Preparation of total cell lysates 
HUVECs were grown until reaching confluency in 60 mm dishes and then treated as 
indicated. Cells were washed once with PBS and afterwards lysed in a modified RIPA 
lysis buffer. Next, cells were stored at -80 °C until further usage. After thawing on ice, cells 
were carefully scraped off, transferred to Eppendorf tubes (Peske, Aindling-Arnhofen, 
Germany) and centrifuged (14,000 rpm, 10 min, 4 °C). The protein concentration of the 
supernatant was determined by performing a Bradford assay or Pierce assay (only before 
immunoprecipitation and pull-down experiments). The remaining samples were mixed with 
either mercaptoethanol sample buffer (3x) or DTT sample buffer (5x) and finally heated at 
95 °C for 5 min. Until Western blot analysis, samples were stored at -20 °C. 
Table 7  Cell lysis buffer 
 
 
 
 
 
 
 
 
 
 
  
Modified RIPA buffer  
Tris/HCl (pH 7.4) 50 mM 
NaCl 150 mM 
Nonidet NP 40 1 % 
Deoxycholic acid 0.25 % 
SDS 0.1 % 
Na3VO4 0.3 mM 
NaF 1.0 mM 
β-Glycerophosphate 3.0 mM 
Pyrophosphate 10 mM 
H2O  
Complete® EDTAfree 4.0 mM 
PMSF 1.0 mM 
H2O2 600 µM 
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Table 8 Sample buffers 
 
2.3.2 Protein quantification 
In order to obtain equal amounts of protein in all samples, a quantification of the total 
protein content was performed before Western blot analysis. The Bradford assay was 
exerted as standard procedure, whereas the Pierce assay was performed prior to 
immunoprecipitation and pull-down experiments. After determining the samples’ 
differences in protein content, the concentration was adjusted to the lowest concentration 
either with (1x) mercaptoethanol - or with (1x) DTT sample buffer. 
2.3.2.1 Bradford assay 
The Bradford assay was performed as previously described.94 It is based on binding of 
Coomassie Brilliant Blue G250 to amino acids, which can then be detected 
photometrically. 10 μl protein sample were incubated with 190 μl Bradford solution (Roti®-
Quant Bradford Reagent, Carl Roth, Karlsruhe, Germany, 1:5 dilution in water) for 5 min 
upon shaking. Afterwards, the absorbance was measured at 592 nm (Tecan Sunrise™ 
reader, TECAN, Männedorf, Switzerland). A stock solution of bovine serum albumin (BSA) 
(2 mg/ml) was stepwise diluted and then used as protein standard. The actual protein 
concentration of each sample was determined by linear regression. 
2.3.2.2 Pierce assay (Bicinchonic acid assay) 
The bicinchoninic acid (BCA) assay was described previously.95 It is based on a 
colorimetric detection of a protein-dependent copper reduction under alkaline conditions. 
10 µl protein sample were incubated with 200 µl BCA reagent (Interchim, Montulocon, 
France) at 37 °C for 30 min. The absorbance of the colored Cu1+- complex was measured 
5x DTT sample buffer    3x Mercaptoethanol sample buffer 
Tris/HCl (pH 6.8) 3.125 M  Tris/HCl 187.5 mM 
Glycerol 10 ml    Glycerol 30 % 
SDS 5 %    SDS 6 % 
DTT 2 %    Bromphenol blue 0.025 % 
Pyronin Y 0.025 %    H2O  
H2O    ß-mercaptoethanol 12.5 % 
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at 550 nm (Tecan Sunrise™ reader, TECAN, Männedorf, Switzerland). The creation of 
protein standards was described in the section Bradford assay. 
2.3.3 SDS-PAGE electrophoresis 
Proteins were separated by discontinuous SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) as described by Laemmli.96 Equal amounts of protein were loaded on 
polyacrylamide gels, which were composed of a separating and a stacking gel. Depending 
on their mass, proteins were separated using the Mini-PROTEAN 3 electrophoresis 
module (Bio-Rad, Munich, Germany). In order to achieve an optimal separation, the 
concentration of acrylamide (RotiphoreseTM Gel 30, Carl Roth, Karlsruhe, Germany) in the 
separating gel was adapted to the molecular weight of the protein of interest (Table 9). 
Electrophoresis was run at 100 V for 21 min for protein stacking, and at 200 V for about 
45 min for protein separation. The molecular weight of protein bands was indicated by a 
pre-stained protein ladder (PageRulerTM, Fermentas, St. Leon-Rot, Germany). 
Table 9  Acrylamide gels 
 
 
Separating gel 7.5, 10, 15 %  Stacking gel 
RotiphoreseTM Gel 30  25/33.3/50 % RotiphoreseTM Gel 30  17 % 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1 %  SDS 0.1 % 
TEMED 0.1 %  TEMED 0.2 % 
APS 0.05 %  APS 0.1 % 
H2O   H2O  
 
 
 
Protein Acrylamide concentration  
VE-cadherin, p-VE-cad., MYPT, p-MYPT 7.5 % 
ß-actin, cIAP1/2, XIAP, ERK, p-ERK, p38, 
p-p38, JNK, p-JNK, p-PKC substrates 
10 % 
MLC2, p-MLC2, pp-MLC2, RhoA, Rac1 15 % 
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Table 10  Electrophoresis buffer 
 
 
 
 
 
 
 
2.3.4 Tank electroblotting 
After mass-dependent separation by SDS-PAGE, proteins were electroblotted onto a 
nitrocellulose membrane (Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany).97 
Inside a tank filled with 1x tank buffer, the nitrocellulose membrane was placed over the 
separating gel and then clamed together in between pads and blotting paper in a 
sandwich-like structure. The membrane was equilibrated before it’s use with 1x tank buffer 
for 20 min. Proteins attached to SDS migrate towards the anode. Sandwiches were 
mounted in the Mini Trans-Blot® system (Bio-Rad, Munich, Germany), ice-cold 1x tank 
buffer was filled in the chamber and a cooling pack was inserted to avoid excessive 
warming. The protein transfer was performed at 4 °C, 100 V for 90 min. 
Table 11  Tank blotting buffer 
5x Tank buffer  1x Tank buffer 
Tris base 240 mM 5x tank buffer 20 % 
Glycine 195 mM  Methanol 20 % 
H2O   H2O  
 
2.3.5 Immunological detection of proteins 
At first, unspecific protein-binding sites were blocked. For this purpose, the membrane 
was incubated for 2 h at room temperature in either non-fat dry milk powder (Blotto) 5 % 
or BSA 5 %. Afterwards, the immunological detection of the protein of interest was 
achieved through incubation with the respective primary antibody solution at 4 °C 
overnight (Table 13). After four washing steps (5 min each) with PBS containing 0.1 % 
Tween® 20 (PBS-T), the membrane was exposed to the secondary antibody solution, 
followed by four additional washing steps with PBS-T (5min each) and one repeat with 
Electrophoresis buffer 
Tris  4.9 mM 
Glycine 38 mM 
SDS 0.1 % 
H2O  
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PBS only (5 min). All incubation steps were performed under gentle agitation. The protein-
antibody complexes were detected with two different methods, depending on the labeling 
of the secondary antibodies (Table 14): enhanced chemiluminescence or infrared 
imaging. 
2.3.5.1 Enhanced chemiluminescence (ECL) detection 
Membranes were incubated for 2 h with a horseradish peroxidase (HRP)-conjugated 
secondary antibody. HRP is a catalyst for the cleavage of luminol together with H2O2 
under the emission of light. The membranes were either incubated with homemade ECL 
solution for 3 min or with commercially available ECL solution for 1 min (ECL Plus 
Western Blotting Detection Reagent RPN 2132, GE Healthcare, Munich, Germany). The 
appearing luminescence was detected by exposure of the membrane to a X-ray film 
(Super RX, Fuji, Düsseldorf, Germany). After a certain exposition time, the film was 
developed with the Curix 60 Developing system (Agfa-Gevaert AG, Cologne, Germany). 
Table 12 ECL solution 
Homemade ECL 
Tris base (pH 8.5) 100 mM 
Luminol 2.5 mM 
p-Coumaric acid 1 mM 
H2O2 17 µM 
H2O  
 
2.3.5.2 Infrared imaging 
Moreover, secondary antibodies coupled to Alexa Fluor® 680 (emission at 700 nm) and 
IRDye™ 800 (emission at 800 nm) were used. Under exclusion of light, membranes were 
incubated for 1 h and subsequently washed as described above. Protein bands were 
detected with the Odyssey imaging system (Li-COR Biosciences, Lincoln, NE, USA).  
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Table 13  Primary antibodies 
Antigen Source Dilution In Provider 
β-actin  mouse monoclon. 1:1,000 Blotto 5 % Millipore 
cIAP1 goat polyclon. 1:1,000 Blotto 2 % Epitomics 
cIAP2 rabbit monoclon. 1:500 BSA 5 % R&D systems 
c-Myc mouse monoclon. 1:1,000 Blotto 5 % Santa Cruz 
p-ERKT202/Y204 mouse monoclon. 1:1,000 BSA 5 % Cell Signaling 
ERK rabbit polyclon. 1:1,000 BSA 5 % Cell Signaling 
FLAG mouse monoclon. 1:100 Blotto 5 % Sigma Aldrich 
p-JNKT183/Y185 mouse monoclon. 1:500 BSA 5 % Cell Signaling 
JNK rabbit polyclon. 1:500 BSA 5 % Cell Signaling 
pp-MLC2T18/S19 rabbit polyclon. 1:1,000 BSA 5 % Cell Signaling 
p-MLC2S19 mouse monoclon. 1:1,000 Blotto 5 % Cell Signaling 
MLC2 rabbit polyclon. 1:500 Blotto 5 % Santa Cruz 
p-MYPT1T696 rabbit polyclon. 1:1,000 Blotto 5 % Santa Cruz 
MYPT1 rabbit polyclon. 1:1,000 Blotto 5 % Santa Cruz 
p-p38T180/Y182 rabbit polyclon. 1:1,000 BSA 5 % Cell Signaling 
p38 rabbit polyclon. 1:1,000 BSA 5 % Cell Signaling 
p-PKC substrates rabbit polyclon. 1:1,000 BSA 5 % Cell Signaling 
Rac1 mouse monoclon. 1:1,000 BSA 3 % Thermo Fisher 
RhoA rabbit monoclon.  1:750 BSA 3 % Thermo Fisher 
p-VE-cadherinY731 rabbit polyclon. 1:1,000 BSA 3 % Biosource 
VE-cadherin mouse monoclon. 1:1,000 Blotto 5 % Santa Cruz 
XIAP mouse monoclon. 1:1,000 Blotto 5 % BD Biosciences 
Table 14  Secondary antibodies 
Antibody Dilution In Provider 
Alexa Fluor® 680 goat anti-mouse 1:20,000 Blotto 1 % Molecular Probes 
IRDye™ 800CW goat anti-rabbit 1:20,000 Blotto 1 % LI-COR Bioscie. 
Donkey anti-goat: HRP 1:1,000 Blotto 1 % Santa Cruz 
Goat anti-mouse IgG1:HRP 1:1,000 Blotto 1 % Biozol 
Goat anti-mouse IgG2b:HRP 1:1,000 Blotto 1 % Southern Biotech. 
Goat anti-rabbit: HRP 1:1,000 Blotto 1 % Dianova 
Goat anti-rabbit: HRP 1:1,000 Blotto 5 % Thermo Fisher 
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2.4 Macromolecular permeability measurement 
Filter membranes of Transwell® plate inserts (pore size 0.4 µm, 12 mm diameter, 
polyester membrane, Corning, New York, USA) were coated with collagen G. The lower 
chambers were filled with 1.5 ml ECGM. 500 µl HMECs in suspension with ECGM 
(0.125 x 106 cells/well) were seeded onto the upper compartment and grown to 
confluence for 24-48 h. Cells were treated as indicated following two different schemes: 
1) Generally, the different inhibitors were pre-incubated for 30 min, before FITC-dextran 
(40 kDa, 1 mg/ml; Sigma-Aldrich, Taufkirchen, Germany) was added to the upper 
compartment at t = 0 min. Subsequently, thrombin receptor activating peptide (TRAP) 
(Mo-Bi-Tec, Göttingen, Germany) or media control was added. 2) Alternatively, cells were 
loaded initially with FITC-dextran (t = 0 min). Thereupon, the compound of interest was 
added. In both cases, samples were taken from the lower compartment at indicated time 
points (Fig. 7). The fluorescence intensity (excitation 485 nm; emission 535 nm) of the 
samples was measured with a microplate reader (SpectraFluor Plus, Tecan, Männedorf, 
Switzerland). The mean fluorescence of untreated cells at the final time point was set as 
1. Data are expressed as relative changes compared to control levels. 
 
 
 
 
Figure 7. Drawing of a single Transwell® plate insert to determine macromolecular permeability. 
After treatment, the upper compartment was loaded with FITC-dextran (40 kDa). At different points in time, the 
flux of the tracer across an HMEC monolayer and a microporous membrane was determined by picking of 
samples from the lower compartment. 
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2.5 Transendothelial electrical resistance (TEER) 
Intercellular junctions limit the net ion flux across endothelial cell layers, and thus function 
as biological resistors. TEER measurement was performed with an Ussing-like chamber, 
engineered and custom-built by Prof. Dr. W. Nagel (Department of Physiology, 
LMU Munich, Germany).98, 99 HUVECs (0.24 x 106 cells/well) were seeded onto collagen 
A-coated Millicell® polycarbonate filter (PCF) inserts (pore size 0.4 µm, 12 mm diameter, 
Merck Millipore, Darmstadt, Germany) and grown to confluence for 24 h. The device was 
pre-heated to 37 °C for 90 min. Cell inserts were carefully placed into the chamber, which 
was subsequently filled with HEPES + 10 % FCS buffer. Bidirectional square current 
pulses of 50 µA (200 ms duration) were applied every third second. A custom-built 
voltage/current clamp unit in connection with a computer-supported evaluation program 
was utilized to calculate TEER according to Ohm’s law. HUVECs were treated with ABT 
30 min in prior to TRAP exposure. The device’s and medium’s own resistance was 
determined after addition of Triton X-100 (Merck, Darmstadt, Germany), which was then 
subtracted to obtain the cell-specific resistance. The resistance immediately before TRAP 
addition was used as control and therefore set as 100 %.  
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2.6 Impedance measurement 
Real-time measurement of impedance was performed with the xCELLigence™ Real-Time 
Cell Analyzer (RTCA) DP (Roche Diagnostics, Mannheim, Germany) consisting of a 
RTCA DP Analyzer, a personal computer-based RTCA control unit and disposable 
E-Plates 16. The manufacturer’s instruction was the basis of all performed experiments. 
Solid gold E-plate 16 electrodes were coated with collagen G for 30 min, then drained and 
refilled with 100 µl ECGM for impedance background measurement. HMECs were seeded 
at a density of 40,000 cells/well on the electrodes. After sedimentation of cells at room 
temperature for 30 min, E-Plates were placed into the RTCA DP Analyzer for recording 
impedance, which is expressed as Cell Index (CI) values. CI is a dimensionless parameter 
based on relative impedance changes. Of note, xCELLigence™ utilizes three different AC 
frequencies (10, 25, and 50 kHz) to measure CI levels. Initial CI values are determined by 
electric conductance of the medium only, but then CI values rise upon increasing cell-
electrode contacts. These are caused at an early stage by cell sedimentation and 
spreading and later on by cell proliferation. Experiments were performed at constant CI 
levels, indicating confluence of the cell monolayer. After treating cells as indicated, 
alterations of CI values occurred from changes of the cell morphology, altered cell-cell, or 
cell-substratum contacts (Fig. 8). CI levels were recorded every 15 min to monitor cell 
growth, but was accelerated up to every 10 s directly before treatment for a time range of 
about 4 h.  
 
 
Figure 8. Principle of impedance measurement. The applied alternating current (AC) passes in 
dependence of the AC frequency either through intercellular clefts (at lower frequencies) or through the cell 
body (at higher frequencies). 
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2.7 Transfection of cells 
HUVECs were transiently transfected with the indicated siRNAs, thus initiating RNA 
interference (RNAi), or with plasmids encoding for wild type or mutant proteins, hence 
inducing protein overexpression. The work of the Nobel Laureates Fire and Mello 
introduced RNAi as efficient method to induce gene silencing.100 Electroporation with the 
Amaxa™ HUVEC Nucleofector kit and device (Lonza, Cologne, Germany) was used 
exclusively to introduce siRNA, whereas the non-lipid cationic Targefect-HUVEC kit 
(Targeting Systems, El Cajon, CA, USA) was used for the delivery of both siRNA and 
plasmids. Cells were used for Western blot, immunocytological staining, and precipitation 
experiments 24 h or 48 h post transfection.  
2.7.1 Transfection with siRNA 
For gene silencing, smartpool siRNAs of XIAP (ON-TARGETplus SMARTpool, Human 
BIRC4; Thermo Scientific, Dreieich, Germany) and cIAP1 (ON-TARGETplus SMARTpool, 
Human BIRC2; Thermo Scientific), each consisting of four different siRNA sequences, 
were used. Non-targeting siRNA (ON-TARGETplus siCONTROL; Thermo Scientific) was 
used as control. The siRNAs were suspended in 1x siRNA buffer (Thermo Scientific) and 
stored as aliquots at -80 °C. The siRNA concentration was verified with NanoDrop® 
(Peqlab, Wilmington, DE, USA).  
For Amaxa™-based transfections, 2 x 106 HUVECs were suspended in 100 µl HUVEC 
Nucleofector solution, 10 µl of the corresponding siRNA (20 µM) was added and then 
transfected (program A-034). After addition of pre-warmed cell culture medium (900 µl), 
cells were cultured under standard conditions for further use.  
For RNA silencing with the Targefect-HUVEC kit (Targeting systems), approximately 
2 x 106 HUVECs were seeded into 25 cm2 cell culture flasks. After 24 h, cell growth 
medium was replaced by 2.5 ml DMEM/High Glucose and the transfection complex was 
added drop wise. This complex consists of DMEM/High Glucose (600 µl), the respective 
siRNA (29 µl, 20 µM), Targefect F2 (14 µl) and Virofect (30 µl), all mixed by only flicking. 
Subsequently, the complex was activated at 37 °C for 20 min. After 90 min on cells, the 
transfection complex was replaced by growth medium. After another 24 h in a 25 cm2 
flask, cells were re-seeded in their final container and were ready for examination. 
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2.7.2 Transfection of plasmids 
In order to induce overexpression of RhoA in HUVECs the Targefect-HUVEC kit 
(Targeting Systems) was utilized. Therefore, the following plasmids were purchased from 
Addgene (Cambridge, MA, USA): pcDNA3-EGFP (plasmid 13031), pcDNA3-EGFP-RhoA 
wild-type (plasmid 12965). 50 x 103 HUVECs were seeded into µ-slides (Ibidi GmbH, 
Martinsried, Germany) for 24 h. After one washing step with DMEM/High Glucose, cells 
were incubated with the Targefect transfection complex for 90 min. The transfection 
complex for one single well consists of DMEM/High Glucose (110 µl), the respective 
plasmid (10 ng), Targefect F2 (0.7 µl) and Peptide Enhancer (2.1 µl). The complex was 
mixed by only flicking and heat-activated for 25 min at 37 °C. After the incubation time, the 
complex was removed and cells were cultured for 24 h under normal conditions and were 
then used for F-actin staining.  
Transfection of HEK 293T cells with pRK5-Myc-RhoA wild-type (Addgene, Cambridge, 
MA, USA), pRK5-Myc-RhoA Q63L (Addgene), pRK5 N19T (Addgene), pEGZ-Flag-EV 
(cloned in the Rajalingam lab) and pEGZ-Flag-XIAP (Rajalingam lab) was carried out with 
GeneJuice® transfection reagent (Novagen®, Merck Millipore, Schwalbach, Germany), at a 
final concentration of 1 μg/ml. The transfection of HEK 293T cells and the subsequent 
immunoprecipitation experiments were kindly performed by T. Oberoi from the group of 
Dr. K. Rajalingam, Institute for Biochemistry II, Goethe-University Medical School, 
Frankfurt/Main, Germany.  
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2.8 Immunofluorescence and confocal laser scanning 
microscopy 
HUVECs were cultured until confluence on collagen G-coated 8 well µ-slides (ibidi, 
Martinsried, Germany). Cells were treated as indicated, washed once with warm PBS+ 
and fixed with 4 % Accustain® paraformaldehyde (Applichem, Darmstadt, Germany) at 
room temperature for 10 min. After three washing steps with PBS, HUVECs were 
permeabilized for 2 min with 0.2 % Triton X-100/PBS and again washed three times. 
Unspecific antibody binding is prevented by blocking with 0.2 % BSA/PBS for 20 min. The 
primary antibodies in 0.2 % BSA/PBS were added over night at 4 °C. After three washing 
steps with PBS, cells were incubated for 45 min at room temperature with the respective 
AlexaFluor®-labeled secondary antibodies or rhodamine-phalloidin for F-actin staining in 
0.2 % BSA/PBS. Finally, cells were washed again three times with PBS, then situated in 
FluorSaveTM Reagent mounting medium (Merck, Darmstadt, Germany) and covered with 
8 mm x 8 mm glass coverslips (custom made by Helmut Saur Laborbedarf, Reutlingen, 
Germany). Samples were stored protected from light at 4 °C. 
Images were acquired with a Zeiss LSM 510 META confocal microscope (40x or 63x oil 
objective, Zeiss, Oberkochen, Germany). 
Table 15  Primary antibodies 
Antigen Source Dilution In Provider 
pp-MLC2T18/S19 rabbit polyclon. 1:400 BSA 0.2 % Cell Signaling 
Table 16  Secondary antibodies 
Antibody/dye Dilution In Provider 
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) 
1:400 BSA 0.2 % Molecular 
Probes 
rhodamine-phalloidin 1:400 BSA 0.2 % Molecular 
Probes 
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2.9 Affinity precipitation of small GTPases 
The affinity precipitation (also called pull-down assay) is a fast tool to monitor the 
activation state of small GTPases.101, 102 Only the active, GTP-bound form can interfere 
with its specific downstream effector (Fig. 9). In this approach, the effector’s GTPase-
binding domain is expressed as recombinant fusion protein with glutathione S-transferase 
(GST). Glutathione agarose beads bind (or pull down) the GST fusion proteins, where the 
activated GTPases are attached. After washing and centrifugation steps, the activated 
GTPases are separated from the total cell lysate and can be analyzed by Western blot. 
The activation state of RhoA and Rac1 were analyzed with active pull-down and detection 
kits (Thermo Scientific, Dreieich, Germany). HUVECs were grown until confluence in 
100 mm dishes and then treated as indicated. The experiments were conducted after the 
manufacturer’s instructions. The provided lysis/binding/washing buffer was supplemented 
with aprotinin (10 µg/ml), leupeptin (10 µg/ml) and PMSF (1 mM). Of note, the entire 
experiment was performed exclusively at 4 °C. The Pierce assay was performed in order 
to correctly adjust the protein content. A part of the RhoA and Rac1 affinity precipitations 
was kindly performed by S. Leonhardt during her Master thesis in the Vollmar lab, 
Department of Pharmacy, Pharmaceutical Biology, LMU Munich, Germany.  
 
 
 
Figure 9. Principle of a RhoA affinity precipitation. Active, GTP-loaded RhoA binds selectively to a 
Rhotekin-GST fusion protein. Rhotekin is a specific RhoA downstream effector. The complex is pulled down 
by glutathione-agarose beads and analyzed by Western blotting. 
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2.10 Immunoprecipitation 
Physical protein interaction was determined by immunoprecipitation experiments. 
HUVECs were grown until confluence in 60 mm cell culture dishes and then treated as 
indicated. Of note, the lysis/binding/washing buffer of the RhoA pull-down kit (Thermo 
Fisher, Dreieich, Germany), supplemented with aprotinin (10 µg/ml), leupeptin (10 µg/ml) 
and PMSF (1 mM) was used. Cells were scrapped off and transferred into Eppendorf 
caps, vortexed vigorously and incubated on ice for 5 min. Thereafter, the cell lysate was 
centrifuged (16,000 g, 15 min, 4 °C) and the protein concentration of the supernatant was 
adjusted using the Pierce method. Subsequently, 5 µl of the respective precipitation 
antibody was added and samples were kept under gentle agitation at 4 °C overnight. 
Protein A (Sigma Aldrich, Taufkirchen, Germany)-agarose beads (for rabbit IgG) and 
protein G (Calbiochem, Darmstadt, Germany)-agarose beads (for mouse IgG) were 
washed with lysis/binding/washing buffer and 60 µl bead suspension was added to each 
sample. After 3 h incubation, under constant agitation at 4 °C, the beads were centrifuged 
(14,000 g, 45 s, 4 °C) and the supernatant was collected as binding control. The bead 
pellet was washed three times with 500 µl lysis/binding/washing buffer and was again 
centrifuged (14,000 g, 45 s, 4 °C). Next, samples were filled up with 25 µl (3x)- and 25 µl 
(1x)-mercaptoethanol sample buffer and heated to 95 °C for 5 min. Samples were stored 
at -20 °C until Western blot analysis was performed.  
For detection of RhoA-XIAP interaction after overexpression, the co-transfected HEK 
293T cells were lysed 48 h post transfection with lysis buffer as previously described.103 
Myc-tagged RhoA was then incubated overnight with an anti-Myc antibody (Santa Cruz, 
Heidelberg, Germany). The antigen-antibody complex was precipitated with sepharose-
coupled protein A/G beads (Roche, Mannheim, Germany), and purified by several 
washing steps with lysis buffer. Proteins were identified with Western blot analysis. The 
immunoprecipitation of RhoA-XIAP in co-transfected HEK 293T cells was kindly 
performed by T. Oberoi from the group of Dr. K. Rajalingam.  
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2.11 GST pulldown assay 
GST fusion proteins of RhoA wild-type, RhoA Q63L (constitutively active mutant) and 
RhoA T19N (dominant negative mutant) were purified according to standard procedures. 
The fusion proteins were used for precipitation of recombinant XIAP as described 
previously.103 Briefly, GST proteins were incubated with glutathione-sepharose beads 
(Sigma Aldrich, Taufkirchen, Germany) in binding buffer for 1 h at 4 °C on a rotator. Beads 
were washed three times with binding buffer and pelleted by centrifugation. Unspecific 
binding was blocked by incubation with 5 % BSA containing binding buffer for 1-2 h. 
Beads were again washed three times and then incubated with purified XIAP 
(R&D Systems, Wiesbaden, Germany) at 4 °C on a rotator for 1 h. Finally, the beads were 
washed with high-stringency binding buffer and boiled at 100 °C for 5 min in 50 µl sample 
buffer. The interaction between the proteins was detected by Western blotting. The assay 
was kindly performed by T. Oberoi from the group of Dr. K. Rajalingam. 
2.12 Cytosolic calcium imaging 
Changes of the cytosolic calcium concentration were detected ratiometrically using the 
fluorescent dye Fura-2.104 The excitation maximum of Fura-2 is strictly calcium dependent 
(unbound state excitation: 380 nm; Ca2+-loaded Fura-2 excitation: 340 nm), whereas the 
emission wavelength remains unchanged (emission: 510 nm). Thus, the excitation ratio of 
340/380 can be directly correlated to the amount of cytosolic calcium. In our 
measurements, a membrane-permeable derivative called Fura-2-acetoxymethyl ester 
(Fura-2-AM) was utilized. After ester cleavage through intracellular esterases, Fura-2 
accumulates within the cytosol. 
HUVECs were grown to confluence in collagen G-coated 8 well µ-slides (ibidi, Martinsried, 
Germany) and experiments were performed at 37 °C. Cells were loaded for 30 min with 
2 μM Fura-2-AM (Biotrend, Cologne, Germany) in HEPES buffer. Concomitantly, HUVECs 
were incubated with ABT (1 µM) or only vehicle for control experiments. After washing the 
cells twice, ABT or vehicle was added again. 1 min after starting the measurement, cells 
were treated with TRAP (50 µM) (Mo-Bi-Tec, Göttingen, Germany) using a mechanical 
injection. Fluorescence measurements were obtained by a Zeiss Axiovert 200 inverted 
microscope (40x objective) with a climatic chamber, a Polychrome V monochromator and 
an IMAGO-QE camera (TILL Photonics, Gräfelfing, Germany). For each sample, a total 
period of 15 min with images being acquired every 5 s was analyzed with the TILLvisION 
Software 4.0.1.2 (TILL Photonics). Each data point of the different graphs was calculated 
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from a randomly chosen rectangle containing at least 20 adjacent cells. Mean values are 
expressed. The cytosolic calcium imaging was kindly performed by Dr. E. A. Willer, 
Department of Pharmacy, Pharmaceutical Biology, LMU Munich, Germany. 
2.13 Statistical analysis 
Each experiment was performed at least three times; the precise number of independent 
repetitions is denoted in the respective figure legend. In the case of HUVECs, a different 
preparation (i.e. cells from a different donor) was utilized each time. Representative 
Western blot images and plot diagrams are shown. Bar graph data are standardized to 
control measurements and expressed as mean ± S.E.M. Statistical analysis was 
performed using the GraphPad Prism software version 5.04 (GraphPad Software, San 
Diego, CA, USA). For analyzing three or more groups, a one-way analysis of variance 
(ANOVA) followed by a Newman-Keuls post-test was carried out. Statistical significance 
was assumed if p ≤ 0.05.  
 
3 RESULTS 
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3.1 Inhibitor of apoptosis proteins regulate endothelial 
barrier function through control of RhoA 
A precursor study from our group demonstrated that inhibition of IAPs reduced leukocyte 
extravasation,4 a phenomenon strongly associated with endothelial hyperpermeability.105-
107 Therefore, we hypothesized that IAPs present a group of unknown regulators of 
endothelial integrity. Consequently, we aimed to identify the potential of IAPs as drug 
targets in endothelial barrier dysfunction and to elucidate the role of different IAPs 
(cIAP1/2, XIAP) in the underlying signaling pathways. 
3.1.1 IAP antagonists prevent TRAP-induced endothelial barrier 
dysfunction 
To elucidate the involvement of IAPs in the regulation of endothelial permeability, we 
tested the potential of IAP antagonists to inhibit TRAP-mediated endothelial barrier 
disruption. Hence, we performed the most prevalent in vitro methods in permeability 
research: the measurement of macromolecular flux across endothelial cells (Fig. 10) and 
transendothelial electrical resistance (Fig. 11).1 
3.1.1.1 IAP antagonists diminish TRAP-caused hyperpermeability of 
macromolecules 
The flux of macromolecules across a HMEC monolayer was determined with two-
compartment Transwell® plates (pore size 0.4 µm; Corning). Pretreatment of endothelial 
cells with two structurally different IAP antagonists (ABT, Smac085) significantly reduced 
the thrombin receptor-activating peptide (TRAP)-induced passage of the labeled tracer 
macromolecule, FITC-dextran (40 kDa), through interendothelial junctions (Fig. 10). The 
time course diagrams show that the flux of FITC-dextran was reduced by both IAP 
antagonists at any observed time point (Fig. 10A, B). The respective statistical endpoint 
analysis (after 30 min) reveals a reduction of TRAP-evoked hyperpermeability by both IAP 
antagonists (1 µM) of approximately 50 % (Fig. 10C, D).   
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Figure 10.  IAP antagonists diminish TRAP-caused hyperpermeability of macromolecules. 
Macromolecular permeability of FITC-dextran (40 kDa) was measured with a Transwell® two-compartment 
system. Cells were pretreated for 30 min with ABT (100 nM, 1 µM) (A, C) or Smac085 (1 µM) (B, D). 
Immediately before TRAP addition (50 µM), FITC-dextran was added (t = 0 min). Samples were taken from 
the lower compartment  at indicated time points. (C, D) The bar diagrams show the statistical endpoint 
analysis at t = 30 min. Data are expressed as mean ± S.E.M. *P ˂ 0.05 in relation to TRAP, one-way ANOVA 
followed by Newman-Keuls post-hoc test. (n = 3). 
 
The results showed that IAP antagonists are able to prevent the TRAP-induced increase 
of macromolecular permeability.  
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3.1.1.2 ABT decreases the TRAP-induced drop of transendothelial electrical 
resistance 
The transendothelial electrical resistance (TEER) describes the ion permeability of a cell 
layer and, thus, represents a read-out parameter of the barrier tightness. HUVECs were 
pretreated with ABT for 30 min prior to TRAP addition. A representative graph indicates 
that pre-incubation with ABT weakened the TRAP-initiated drop of TEER values at any 
observed time point (Fig. 11A). Statistical evaluation of all performed experiments shows 
that ABT significantly decreased the maximal TRAP effect, which could be detected 60 s 
after treatment (Fig. 11B). Of note, ABT reduced the maximum response to TRAP by 
30 %.  
 
A        B 
 
 
 
 
 
 
 
Figure 11.  ABT decreases the TRAP-induced drop of transendothelial electrical resistance. TRAP-
induced changes of the cell layers electrical resistance were analyzed with (grey graph) and without (black 
graph) ABT (1 µM) pretreament for 30 min. TRAP (10 µM) was added at t = 0. (A) One representative pair of 
TEER measurements. (B) Statistical evaluation of all performed TEER recordings at t = 60 s (time point of the 
maximum TRAP effect). *P ˂ 0.05 versus TRAP, one-way ANOVA followed by Newman-Keuls post-hoc test. 
(n = 3). 
 
We concluded that ABT protects against the TRAP-induced decrease of electrical 
resistance of an endothelial cell layer.  
Altogether, IAP antagonists (ABT, Smac085) were proven in two functional permeability 
assays (measurement of macromolecular permeability and TEER) to prevent TRAP-
evoked endothelial hyperpermeability.  
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3.1.2 IAP inhibition modulates key parameters of endothelial 
permeability 
Endothelial hyperpermeability results from actomyosin-based contraction followed by a 
disruption of intercellular junctions.20 The beneficial effect of IAP antagonism on key 
parameters of interendothelial adhesion (adherens junctions) (Fig. 12) and cellular 
contraction (stress fiber formation, activation of myosin light chain 2) (Fig. 13, 14) was 
subsequently analyzed. 
3.1.2.1 ABT stabilizes adherens junctions 
It is commonly accepted that adherens junctions (AJs), consisting of homophilic 
extracellular vascular endothelial (VE)-cadherins, are the major regulators of barrier 
function in the vascular system.13, 108, 109 Within the first five minutes of treatment, thrombin 
initiated the phosphorylation of VE-cadherin at Y731, which is a marker for the disruption of 
AJ.108, 110 ABT prevented this phosphorylation event after 15 and 30 min, but left the 
amount of total VE-cadherin unaltered (Fig. 12). 
 
 
 
 
 
Figure 12.  ABT prevents disruption of adherens junctions. HUVECs were treated with ABT (1 µM) 
30 min before thrombin (1 U/ml) addition. The levels of phosphorylated (Y731) and total VE-cadherin were 
analyzed by Westeren blotting. One representative blot out of three independently performed experiments is 
shown. 
 
Our data indicated that ABT protects against thrombin-evoked disassembly of AJs.  
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3.1.2.2 Thrombin-induced F-actin stress fiber formation is suppressed by ABT 
The second key parameter of endothelial hyperpermeability is the rearrangement of the 
actin cytoskeleton into fibrilliar structures, known as stress fibers.111 Immunocytochemistry 
of the F-actin cytoskeleton revealed a strong stress fiber formation upon thrombin 
treatment. Interestingly, ABT-treated HUVECs showed no thrombin-induced stress fibers 
and displayed a phenotype similar to control cells (Fig. 13), demonstrating that IAP 
antagonism abolishes the thrombin-mediated cytoskeletal remodeling. 
 
 
 
 
 
Figure 13  Stress fiber formation is abolished by ABT. HUVECs were either left untreated or pretreated 
with ABT (1 µM) 30 min prior to thrombin (1 U/ml) (5 min) exposure. F-actin distribution was determined by 
confocal laser scanning microscopy. The bar indicates 20 µm. One representative image out of three 
independently performed experiments is shown. 
 
3.1.2.3 ABT inhibits the activation of the contractile machinery 
The phosphorylation status of the myosin light chain2 (MLC2) controls the interaction of 
actin and myosin.27 Mono- and di-phosphorylation of the MLC2 drive the 
mechanochemical force generation for cellular contraction.19 Thrombin rapidly increased 
the phosphorylation of MLC2 (at T18, S19), as detected after 5 min. IAP inhibition by ABT 
prevented the di- (5 and 15 min) as well as the mono-phosphorylation (15 min) after 
thrombin exposure (Fig. 14A).  
Cellular contraction is compensated by activation of myosin light chain phosphatase 
(MLCP), which conducts the dephosphorylation of MLC2. The activity of MLCP is 
regulated by its auto-regulatory subunit myosin phosphatase-targeting subunit 1 
(MYPT1).112 Phosphorylation of MYPT1 at T696 results in phosphatase inhibition113 and is 
enhanced upon thrombin treatment. However, ABT reduced the phosphorylation of 
MYPT1 after 5 and 15 min, thus shifting MLCP towards its active conformation (Fig. 14B).   
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Figure 14.  ABT inhibits the activation of the contractile machinery. HUVECs were either left untreated 
or pretreated with ABT (1 µM) 30 min prior to thrombin (1 U/ml). (A) Phosphorylation of myosin light chain 
(MLC) 2 at T18/S19 and (B) of the myosin phosphatase-targeting subunit (MYPT)1 at T696 was analyzed by 
Western blotting. One representative blot out of three independently performed experiments is shown. 
 
Here, we showed that ABT suppresses the phosphorylation of MLC2 and MYPT1. 
Taken together, ABT positively influenced molecular determinants of endothelial 
hyperpermeability. The disassembly of AJs, the cytoskeletal rearrangement into stress 
fibers as well as the activation of the contractile machinery in response to thrombin were 
rescued by IAP inhibition with ABT.  
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3.1.3 Neither calcium levels, nor PKC or MAPK signaling is 
altered by IAP inhibition 
Next, we wanted to identify the underlying signaling mechanisms of how IAPs regulate 
endothelial barrier function. Thrombin is known to induce endothelial hyperpermeabilitiy 
via distinct signaling transduction systems.114 Therefore, we investigated the influence of 
ABT on calcium levels (Fig. 15) and on important protein kinases (MAPKs, PKC) (Fig. 16, 
17) known to be crucially involved in thrombin-induced endothelial cell permeability. 
3.1.3.1 ABT does not affect cytosolic calcium levels 
Thrombin leads to an increase of intracellular calcium ([Ca2+]i) levels through a 
combination of two distinct mechanisms – the fast depletion of endoplasmatic stores and 
a more sustained influx of calcium ions across the plasma membrane.115 To determine the 
influence of IAP antagonism on [Ca2+]i levels, we performed ratiometric calcium 
measurements with Fura-2-AM. ABT did not affect the rapid thrombin-induced depletion of 
the endoplasmatic reticulum (after 2 min), nor the subsequent sustained plateau phase 
(after 5 min), which is mediated by opening of store-operated channels (SOCs) (Fig. 15). 
 
 
 
 
 
 
 
Figure 15.  ABT does not affect intracellular calcium levels. Thrombin-induced changes of intracellular 
calcium ions were measured in HUVECs loaded with FURA-2-AM. Cells were exposed to ABT (1 µM) (grey 
line) or medium control (black line) for 30 min. Thrombin (1 U/ml) was added at t = 1 min. One representative 
plot out of three independently performed experiments is shown. This assay was kindly performed by Dr. E. A. 
Willer, Department of Pharmacy, Pharmaceutical Biology, LMU Munich, Germany. 
 
This data suggested that ABT has no influence on the thrombin-mediated increase of 
cytosolic calcium.  
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3.1.3.2 ABT does not influence PKC activation 
Since various protein kinase C (PKC) isoforms may contribute to endothelial 
hyperpermeability,36 we checked PKC activity by analyzing the phosphorylation status of 
PKC substrates containing typical S-phosphorylation motives. The observed thrombin-
evoked augmentation of phosphorylated PKC substrates, especially after 5 and 15 min, is 
not affected by pretreatment with ABT (Fig. 16). Thus, ABT does not affect the thrombin-
induced phosphorylation of PKC downstream targets. 
 
 
 
 
 
 
 
 
Figure 16. ABT does not affect activation of PKC. The activation of PKC was investigated by analyzing 
phosphorylation of conventional PKC substrates through Western blotting. HUVECs were challenged with 
ABT (1 µM) or medium control 30 min prior to thrombin (1 U/ml) addition. One representative blot out of three 
independently performed experiments is shown. 
 
3.1.3.3 MAPK activity is not altered by IAP inhibition 
Also the major mitogen activated protein kinases (MAPKs) – extracellular signal-related 
kinase (ERK), p38 and c-jun N-terminal kinase (JNK) – are important regulators of 
endothelial permeability.32, 33, 35 The thrombin-mediated activation of ERK (Fig. 17A), JNK 
(Fig. 17B) and p38 (Fig. 17C) was analyzed at three different time points. Activation of all 
three MAPKs was not affected by pre-incubation with ABT.  
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Figure 17. MAPK activity is not altered by ABT. HUVECs were treated with ABT (1 µM) or medium 
control for 30 min and subsequently with thrombin (1 U/ml). The phosphorylation status of (A) ERK (T202/Y204), 
(B) JNK (T183/Y185) and (C) p38 (T180/Y182) was analyzed by Western blotting. One representative blot out of 
three independently performed experiments is shown. 
 
Hence, we could rule out a role of IAPs in thrombin-activated MAPK signaling. 
In summary, these data excluded an influence of IAPs in calcium, PKC or MAPK signaling 
pathways in the thrombin-activated endothelium. 
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3.1.4 IAP inhibition regulates RhoA activity 
Our previous results clearly indicate a novel role for IAPs in the regulation of endothelial 
barrier function as IAP antagonists protect against TRAP-induced hyperpermeability. The 
analyzed inflammatory signaling pathways (calcium, PKC or MAPK) downstream of 
thrombin receptor activation were not altered by IAP inhibition. Interestingly, we observed 
a strong reduction in stress fiber formation after antagonizing IAPs (Fig. 13). Given that 
small GTPases are master regulators of the actin cytoskeleton rearrangement,116 we 
hypothesized that ABT might influence small GTPases signaling. Consequently, we 
investigated the activation of the small GTPases RhoA and Rac1 (Fig. 18), the total 
protein expression (Fig. 19) and stress fiber formation induced by RhoA overexpression 
(Fig. 20) after ABT treatment. 
3.1.4.1 ABT reduces RhoA activation, but does not affect Rac1 
The effect of IAP inhibition on the barrier disruptive small GTPase RhoA and its 
physiological counterpart Rac147 was investigated by affinity precipitation experiments. 
ABT abolished the thrombin-triggered RhoA activation, as indicated by precipitated RhoA-
GTP levels (Fig. 18A). However, activity of the barrier protective small GTPase Rac1 was 
neither affected by thrombin, nor by ABT (Fig. 18B). 
 
A       B 
 
 
 
 
Figure 18. ABT reduces the activation of RhoA, but not of Rac1. HUVECs were treated with ABT 
(1 µM) or medium control 30 min prior to thrombin (1 U/ml, 10 min). (A) RhoA-GTP and (B) Rac1-GTP were 
precipitated and purified with a pull-down assay and analyzed by Western blotting. One representative blot out 
of at least three independently performed experiments is shown. A part of the performed active RhoA and 
Rac1 pull-down assays was kindly performed by S. Leonhardt, Department of Pharmacy,  Pharmaceutical 
Biology, LMU Munich, Germany. 
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3.1.4.2 Total protein levels of RhoA and Rac1 are not altered 
We additionally analyzed the expression levels of total (GTP- and GDP-bound) RhoA and 
Rac1 in whole cell lysates. Neither ABT, nor thrombin altered the amount of total RhoA 
and Rac1 in HUVECs (Fig. 19). 
 
 
 
 
 
Figure 19. Total protein levels of RhoA and Rac1 are not influenced by ABT and thrombin. HUVECs 
pretreated with ABT (1 µM) for 30 min are subsequently exposed to thrombin (1 U/ml), and then analyzed by 
Western blotting. One representative blot out of three independently performed experiments is shown. 
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3.1.4.3 ABT prevents stress fiber formation induced by RhoA overexpression 
Transient overexpression of RhoA wild-type (wt) is a known inducer of stress fibers.117 
Also in HUVECs with increased RhoA levels, ABT potently inhibited the formation of 
elongated, thick F-actin fibers (Fig. 20). 
 
 
 
 
 
 
 
 
 
Figure 20. ABT prevents RhoA overexpression-induced stress fiber formation. HUVECs were 
transfected with pcDNA3-EGFP or pcDNA3-EGFP-RhoA wild-type (wt). ABT (1 µM) or medium control were 
added for 30 min. F-actin distribution and successful transfection with EGFP-labeled plasmids were analyzed 
by confocal laser scanning microscopy. The bar indicates 10 µm. Representative images out of four 
independently performed experiments are shown. 
 
We demonstrated that IAP antagonism interferes with RhoA signaling. ABT prevented the 
activation of RhoA, but did not influence Rac1, and left the total protein levels of these 
small GTPases unaltered. Furthermore, we revealed that inhibition of stress fiber 
formation by ABT was also observed in a RhoA overexpression system. 
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3.1.5 XIAP is responsible for RhoA activation and cytoskeletal 
rearrangement 
So far, we have described that barrier protective properties of ABT are mediated by 
limiting RhoA activity. Next, we aimed to elucidate the contribution of different IAP family 
members on the observed effects. XIAP, cIAP1 and cIAP2 are the most important and 
best characterized IAP representatives,65 which we consequently focused on. 
3.1.5.1 Characterizing IAP levels after ABT and thrombin treatment 
At first, we analyzed the amount of cIAP1/2 and XIAP in HUVECs under basal conditions 
and after thrombin treatment with or without ABT. Surprisingly, cIAP2 was not expressed 
in untreated or thrombin-conditioned endothelial cells, and therefore excluded from further 
analysis (Fig. 21A). TNFα, a known inducer of cIAP2 expression,118 was used as positive 
control to demonstrate, that our setting is able to detect cIAP2. Thrombin activation of 
HUVECs did not alter the protein levels of cIAP1 and XIAP (Fig. 21B). Interestingly, the 
IAP inhibitor ABT rapidly depleted cIAP1 in HUVECs, whereas XIAP levels remained 
stable (Fig. 21C). 
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Figure 21. IAP levels after thrombin or ABT treatment. Protein levels of cIAP1/2 and XIAP were 
determined by Western blot analysis. Thrombin (1 U/ml) was added for 30 min (A) or as indicated (B, C), 
TNFα (10 ng/ml) for 24 h (A) and ABT (1 µM) 30 min prior to thrombin (C). One representative blot out of three 
independently performed experiments is shown. 
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3.1.5.2 RhoA activation depends on the presence of XIAP rather than on cIAP1 
The role of individual IAPs in RhoA activation was addressed with an RNAi approach. 
Gene silencing of XIAP completely inhibited RhoA activation, whereas loss of cIAP1 
caused only a marginal reduction (Fig. 22). Successful silencing of IAPs was verified in 
total cell lysates. Of note, knockdown of one IAP did not trigger the reciprocal upregulation 
of the other IAP. 
 
 
 
 
 
 
 
Figure 22. Silencing of XIAP prevents RhoA activation. XIAP or cIAP1 were degraded in HUVECs by 
RNAi. Non-targeting siRNA was used as negative control. TRAP (50 µM) treatment for 10 min induced RhoA 
activation. RhoA-GTP was precipitated with a pull-down assay and analyzed by Western blotting. One 
representative blot out of three independently performed experiments is shown.  
 
3.1.5.3 XIAP silencing prevents stress fiber formation and activation of MLC2 
Moreover, activation of the contractile machinery (actin, MLC2) was investigated in 
HUVECs with transiently degraded IAPs. Silencing of XIAP, but not of cIAP1, inhibited the 
TRAP-evoked stress fiber formation as well as the activation of MLC2 (Fig. 23A). 
Knockdown of XIAP induced cortical actin distribution, a phenotype associated with 
endothelial barrier stabilization.119 Successful protein knockdown of cIAP1 and XIAP was 
controlled by Western blotting (Fig. 23B).  
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Figure 23. Silencing of XIAP prevents the activation of the contractile machinery. Non-targeting 
siRNA served as negative control. HUVECs were challenged with TRAP (50 µM) for 10 min. (A) Cells with 
transiently degraded IAPs were stained for F-actin and di-phosphorylated MLC2, and then analyzed by 
confocal laser scanning microscopy. The bar indicates 20 µm. (B) Silencing control of cIAP1 and XIAP 
through Western blot analysis. One representative image/blot out of four independently performed 
experiments is shown. 
 
In summary, we demonstrated that XIAP is the major regulator of RhoA activation and 
subsequent downstream events.   
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3.1.6 XIAP directly interacts with RhoA 
Since XIAP functions as regulator of RhoA activity, we speculated if there might be a 
direct interaction of IAPs with RhoA. Therefore, we analyzed this supposed interaction 
both in vitro and in a cell-free system. 
3.1.6.1 RhoA strongly binds to XIAP 
The association of IAPs with RhoA in endothelial cells was confirmed by performing 
immunoprecipitation experiments. RhoA was found to be firmly attached to XIAP 
immunoprecipitates (Fig. 24A), whereas the interaction of RhoA with cIAP1 was much 
weaker (Fig. 24B). Of note, ABT treatment did not affect the interaction of XIAP and 
RhoA, but diminished the amount of co-precipitated RhoA bound to cIAP1. 
 
A       B 
 
 
 
 
 
Figure 24. RhoA precipitates with XIAP. HUVECs were treated with ABT (1 µM) or medium control for 
30 min. Immunoprecipitation of XIAP (A) and cIAP1 (B) were performed. The IAP-bound RhoA was detected 
by Western blot analysis. One representative blot out of three independently performed experiments is shown. 
 
3.1.6.2 XIAP interacts with RhoA independently of the RhoA activation status 
Finally, we investigated if the RhoA activation status influences the interaction between 
XIAP and RhoA. HEK 293T cells were co-transfected with plasmids encoding for XIAP 
together with either RhoA wild-type (wt) or RhoA Q63L, a constitutively active mutant. 
Overexpressed XIAP was associated both with RhoA wt and with active RhoA (Fig.25A). 
A direct interaction could be proven in a cell-free system, where recombinant GST fusion 
proteins of RhoA wt, the constitutively active RhoA Q63L mutant, as well as the dominant 
inactive RhoA T19N mutant were found to bind to recombinant XIAP (Fig. 25B).  
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Figure 25. XIAP binds RhoA independently of the RhoA activation status. (A) HEK 293T cells were 
co-transfected with the following plasmids: myc-RhoA wild-type (wt) and myc-RhoA Q63L (constitutively 
active), with Flag-XIAP or the respective empty vector (EV). The myc-tag was precipitated with a selective 
anti-myc antibody. Levels of XIAP, RhoA and of the myc- and FLAG-tag were analyzed by Western blotting. 
(B) Recombinant GST-RhoA wt, GST-RhoA Q63L and GST-RhoA T19N (dominant negative) were incubated 
with recombinant XIAP. A GST pull-down assay was performed. Co-precipitated XIAP was detected by 
Western blotting. One representative blot out of three independently performed experiments is shown. These 
experiments were kindly performed by T. Oberoi from the group of Dr. K. Rajalingam, Institute of Biochemistry 
II, Goethe-University Medical School, Frankfurt/Main, Germany. 
 
We identified an interaction of RhoA and XIAP in endothelial cells. Moreover, co-
transfection experiments in HEK 293T cells and GST-pull-down assays of purified 
recombinant proteins not only confirmed our finding, but also demonstrated that this 
interaction is independent of RhoA activation.  
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3.2 A comparative study of in vitro assays for the 
analysis of endothelial permeability 
A typical hallmark of inflammatory processes is the increased vascular permeability and 
the subsequent edema formation.120 Validated in vitro methods are indispensable for the 
identification of novel drug targets in the regulation of endothelial permeability as well as 
for the investigation of the underlying signaling pathways. 
In our study, we compare the following two methods: 1) the classic measurement of 
macromolecular permeability (MP) and 2) the modern real-time cell impedance sensing, 
which employs alternating currents to analyze morphological changes. Endothelial cells 
were challenged with different well-established modulators of the endothelial barrier 
function in both approaches for an unbiased judgment.  
3.2.1 The barrier protective compound forskolin shows congruent 
results in both approaches 
Since many years, the adenylyl cyclase activator forskolin is known to strengthen the 
endothelial barrier.121 This made it an ideal compound for the initial characterization of the 
utilized permeability assays. 
3.2.1.1 Forskolin elevates the Cell index (CI) 
HMECs respond to forskolin addition (at t = -0.5 h) with a gradual increase of normalized 
CI values (Fig. 26A). TRAP induced endothelial hyperpermeability,21 which appears as 
rapid drop of CI values (Fig. 26A, B). Interestingly, the maximum effect caused by TRAP 
was mitigated by forskolin pretreatment in terms of amplitude and duration (Fig. 26B). 
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Figure 26. Forskolin elevates the Cell index. HMECs were treated with forskolin (10 µM) for 30 min and 
subsequently exposed to TRAP (50 µM). The time course of compound-mediated alterations of normalized CI 
is displayed by a representative experiment. CI is normalized either to (A) basal levels (before forskolin 
treatment) or to (B) the time point of TRAP addition. The experiment was performed independently three 
times. 
 
3.2.1.2 Forskolin reduces the TRAP-induced flux of macromolecules 
In our second approach, forskolin limited the passage of FITC-dextran (40 kDa) through a 
HMEC monolayer as assessed with a two-compartment Transwell® assay (pore size 
0.4 µm; Corning). Forskolin reduced the basal permeability (compared to control), and 
fully reversed the TRAP-evoked hyperpermeability (Fig. 27). 
 
 
 
 
 
 
 
 
Figure 27. Forskolin reduces the permeability of macromolecules. HMECs were treated with 
forskolin (10 µM) for 30 min, subsequently FITC-dextran (40 kDa) and TRAP (50 µM) were added. The flux of 
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FITC-dextran across a HMEC layer was measured with a Transwell® two-compartment system. Samples were 
taken from the lower compartment at indicated time points. Data are expressed as mean ± S.E.M.. *P < 0.05 
in relation to control, one-way ANOVA followed by Newman-Keuls post-hoc test. (n = 3). 
 
3.2.1.3 Forskolin prevents the activation of the contractile cytoskeleton 
In order to prove that forskolin positively influences the endothelial barrier function, we 
analyzed the cytoskeletal rearrangement induced by forskolin with our without TRAP. The 
phosphorylation of MLC2, indispensable for the actin-myosin interaction, was enhanced 
5 min after TRAP addition, but could be reduced by forskolin pre-incubation (Fig. 28A). 
Compared to control cells, treatment with only forskolin induced actin assembly in the 
periphery. Moreover, forskolin pretreatment also remodeled the typical TRAP-evoked 
stress fibers into a cortical actin rim (Fig. 28B).  
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Figure 28.  Forskolin prevents the activation of the contractile cytoskeleton. HUVECs were treated 
with forskolin (10 µM) for 30 min before TRAP (50 µM) was added. (A) The di-phosphorylation (T18, S19) of 
MLC2 was analyzed through Western blotting. (B) F-actin distribution was determined by confocal laser 
scanning microscopy. TRAP (50 µM) was added for 10 min. The bar indicates 20 µm. One representative 
blot/image out of three independently performed experiments is shown. 
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Altogether, this accounted for the congruent results of permeability measurement – a 
decreased flux of macromolecules and elevated impedance values caused by forskolin 
treatment. 
 
3.2.2 The transient histamine-induced hyperpermeability is hardly 
detectable by macromolecular permeability measurement 
but with impedance sensing 
The inflammatory mediator histamine causes an immediate activation of the actin 
cytoskeleton thus increasing endothelial permeability.43 We aimed for an analysis of the 
transient cell response to different histamine concentrations. 
3.2.2.1 Real-time impedance measurement of the histamine response 
Impedance-based analysis detects a rapid decline (max. at 1 min) of normalized CI values 
upon histamine addition, which is immediately reversed. The detected drop followed a 
concentration series from 1 µM up to 100 µM (Fig. 29). 
 
 
 
 
 
 
 
 
 
Figure 29. Impedance measurement of the histamine response. HMECs were treated with histamine at 
indicated concentrations. One representative graph out of three independently performed experiments 
indicates the changes of the normalized CI. Normalization to CI values just before histamine treatment. 
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3.2.2.2 Measurement of macromolecular permeability lacks sensitivity for 
histamine-induced hyperpermeability 
Although histamine increased the permeability of macromolecules at any observed time 
point, the assays reliability is very limited. No precise concentration dependence was 
detectable, since the mean of 1 µM histamine was higher than for 10 µM. Moreover, the 
data revealed no statistical difference (at t = 30 min) due to the huge occurring standard 
errors (Fig. 30). 
 
 
 
 
 
 
 
 
Figure 30. MP measurement after histamine treatment. HMECs were treated with histamine at indicated 
concentrations. Macromolecular permeability of FITC-dextran (40 kDa) was measured with a Transwell® two-
compartment system, where samples were taken from the basolateral side at indicated time points. Data are 
expressed as mean ± S.E.M.. *P < 0.05 in relation to control, one-way ANOVA followed by Newman-Keuls 
post-hoc test. ( n = 5). 
We demonstrated that the rapid and very transient effect of histamine could reliably be 
detected in a concentration-dependent manner by real-time impedance sensing. In 
contrast, the MP approach was lacking sensitivity, which caused huge standard errors and 
no clear relation between the applied concentrations and the measured response.  
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3.2.3 Inhibition of RhoA kinase (ROCK) increases basal 
permeability, but prevents TRAP-triggered barrier disruption 
ROCK, a downstream target of active RhoA, induces phosphorylation of MYPT1, and 
therefore alters the endothelial barrier function (see 1.2.3.4). We analyzed the endothelial 
response to the blocking of ROCK by the pharmacological inhibitor Y-27632 in the two 
permeability detection systems.  
3.2.3.1 Y-27632 itself decreases CI values, but also limits the TRAP response 
Treatment of HMECs with Y-27632 induced a sustained and strong reduction (30 %) of 
the normalized basal CI values within 30 min. In contrast, TRAP addition caused a 
transient, less pronounced drop (15%) of normalized CI levels (Fig. 31A). Interestingly, 
pretreatment with Y-27632 weakened the TRAP response in terms of amplitude and 
duration (Fig. 31B). 
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Figure 31. Y-27632 itself decreases CI values, but limits the TRAP response. HMECs were treated 
with Y-27632 (10 µM) for 30 min before TRAP (50 µM) was added. (A) CI is normalized to basal levels (before 
Y-27632 treatment). (B) The TRAP-induced drop of CI values below the control levels is displayed. One 
representative graph out of three independently performed experiments is shown. 
 
3.2.3.2 Y-27632 itself elevates macromolecular permeability, but also abolishes the 
TRAP-evoked increase of permeability 
ROCK inhibition with Y-27632 (10 µM) significantly elevated the flux of macromolecules 
across a HMEC monolayer by about 30 % within 30 min (Fig. 32A). Of note, TRAP 
treatment doubled the passage of FITC-dextran after 60 min. However, the TRAP-initiated 
increase in MP could be fully prevented by Y-27632 pre-incubation (Fig. 32B). 
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Figure 32. Y-27632 itself elevates MP, but protects against TRAP effects. (A) HMECs were treated 
with Y-27632 at indicated concentrations immediately before FITC-dextran (40 kDa) was added. (B) HMECs 
were pre-incubated with Y-27632 (10 µM) 30 min, then FITC-dextran (40 kDa) and successively TRAP 
(50 µM) were added. The passage of FITC-dextran across the cell layer was measured with a Transwell® two-
compartment system. Samples were taken from the lower compartment at indicated time points. Data are 
expressed as mean ± S.E.M.. *P < 0.05 in relation to control, one-way ANOVA followed by Newman-Keuls 
post-hoc test. (n = 3). 
 
3.2.3.3 Y-27632 inhibits the activation of MLC2 and stress fiber formation 
Y-27632 completely abolished basal and TRAP-evoked phosphorylation of MLC2 
(Fig 33A, B). Also the TRAP-induced actin remodeling into stress fibers was prevented by 
Y-27632 pretreatment (Fig. 33B). 
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Figure 33.  Y-27632 prevents the activation of the contractile cytoskeleton. HUVECs were treated with 
Y-27632 (10 µM) for 30 min before TRAP (50 µM) was added. (A) The di-phosphorylation (T18, S19) of MLC2 
was analyzed through Western blotting. (B) F-actin distribution and di-phosphorylation of MLC2 were 
determined by confocal laser scanning microscopy. TRAP (50 µM) was added for 10 min. The bar indicates 
20 µm. One representative blot/image out of three independently performed experiments is shown. 
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We revealed that ROCK inhibition with Y-27632 initially increased the permeability of 
endothelial cells. Surprisingly, we detected a massive drop of impedance values (about 
200 % of the TRAP effect), but only a slight increase in FITC-dextran flux (only about 
30 % of the TRAP effect). Nevertheless, Y-27632 diminished the TRAP-mediated 
endothelial hyperpermeability in terms of impedance sensing, MP measurement and 
stress fiber formation.  
 
3.2.4 Controversial results upon inhibition of myosin 
As actomyosin interaction is indispensable for the regulation of the endothelial barrier, we 
further characterized the influence of blebbistatin – a selective myosin II inhibitor – known 
to detach myosin II from actin, in the two permeability detection systems.122 
3.2.4.1 Blebbistatin alone decreases CI values and abrogates the TRAP effect 
Blebbistatin immediately induced a decrease of normalized CI values – about 20 % within 
30 min and 40 % after 3 h. Furthermore, blebbistatin fully prevented the typical TRAP-
triggered drop of CI values (Fig. 34). 
 
 
 
 
 
 
 
 
Figure 34 Blebbistatin alone decreases the CI and abrogates the TRAP effect. HMECs were treated 
with blebbistatin (10 µM) for 30 min and subsequently exposed to TRAP (50 µM). The time course of 
compound-mediated alterations of normalized CI is displayed by a representative experiment. CI is normalized 
to basal levels (before blebbistatin treatment). Three independent experiments were performed. 
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3.2.4.2 Blebbistatin does not affect macromolecular permeability 
Blebbistatin did not influence the endothelial permeability of FITC-dextran compared to 
untreated cells over a time period of 90 min (Fig. 35A). Moreover, also the TRAP-induced 
increase of MP is not altered by blebbistatin pretreatment (Fig. 35B). 
 
A  
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
Figure 35 Blebbistatin does not affect MP. (A) HMECs were treated with blebbistatin at indicated 
concentrations immediately before FITC-dextran (40 kDa) was added. (B) HMECs were exposed to 
blebbistatin (10 µM) for 30 min, then FITC-dextran (40 kDa) and successively TRAP (50 µM) were added. 
(A, B)The passage of FITC-dextran across the cell layer was measured with a Transwell® two-compartment 
system. Samples were taken from the lower compartment at indicated time points. Data are expressed as 
mean ± S.E.M.. *P < 0.05 in relation to control, one-way ANOVA followed by Newman-Keuls post-hoc test. 
(n = 3).  
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3.2.4.3 Blebbistatin does not influence the contractile cytoskeleton 
Immunofluorescence staining of F-actin and phosphorylated MLC2 revealed no major 
alterations of blebbistatin treated cells – neither under control conditions nor after TRAP 
activation (Fig. 27). 
 
 
 
 
 
 
 
 
 
 
Figure 36  Blebbistatin does not influence the contractile cytoskelton. HUVECs were treated with 
blebbistatin (10 µM) for 30 min before TRAP (50 µM) was added for 10 min. F-actin distribution and di-
phosphorylation of MLC2 (T18,S19) were determined by confocal laser scanning microscopy. The bar indicates 
20 µm. One representative image out of three independently performed experiments is shown. 
 
We found discrepancies in MP and impedance measurement when endothelial cells were 
challenged with the myosin II inhibitor blebbistatin. Although blebbistatin itself decreased 
the impedance signal, it still fully abrogated the TRAP-induced drop of impedance values. 
In contrast to these observations, blebbistatin exerted no effect on the passage of 
macromolecules and did not affect the contractile cytoskeleton. 
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4.1 Targeting endothelial hyperpermeability as 
promising anti-inflammatory strategy 
Inflammation is a protective attempt to resolve infections or tissue injury. Circulating 
leukocytes run through the adhesion cascade – including the steps of capturing, rolling, 
activation, firm adhesion and transmigration – to overcome the endothelial barrier in order 
to counteract invading pathogens at the site of inflammation.105 Nevertheless, an 
exceeding or permanent inflammatory activation is harmful to the host and results in 
inflammation-related disease progression. The release of inflammatory mediators, 
reactive oxygen species (ROS) and cytotoxic enzymes from leukocytes as well as the 
subsequently induced edema formation causes serious tissue damages and organ 
dysfunction. For decades, the interaction between leukocytes and microvessel walls has 
been considered as critical step for tissue injury.123 Consequently, research efforts majorly 
focused on the inhibition of specific adhesive ligands mediating leukocyte–endothelium 
interaction.123-126 However, this anti-adhesive strategy has not shown benefits in clinical 
trials.127 This might be explained by recent studies, which suggested that the process of 
leukocyte adhesion and migration is not directly responsible for vascular leakage, but 
might be induced by the release of inflammatory mediators and ROS.123, 128, 129  
These findings suggest the direct targeting of endothelial hyperpermeability as promising 
approach to prevent vascular damage during inflammation. Thus, not only the direct 
effects of inflammatory mediators on endothelial cells, but also the leukocyte-associated 
increase of permeability should be attenuated.123 
 
Therefore, we characterized novel targets in the regulation of endothelial permeability and 
evaluated the most appropriate methods for the analysis of barrier function: 
(1) We disclosed IAPs as novel regulators of endothelial hyperpermeability and RhoA 
activation in response to thrombin. In consequence, IAP antagonism was proven to 
successfully protect the endothelial barrier against thrombin-mediated stress fiber 
formation, cell contraction and destabilization of AJs.  
(2) Moreover, we for the first time compared the advantages and limitations of classic 
macromolecular permeability measurement and sophisticated impedance sensing as 
methods for the analysis of endothelial barrier function in vitro.  
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4.2 The role of IAPs in inflammation 
Beyond their prominent role in cancer cell biology, IAPs emerged as regulators of signal 
transduction events that promote inflammation. Numerous studies highlighted the 
importance of IAPs as modulators of NFκB and MAPK activation in TNF-receptor (TNFR) 
signaling.130-132 For example, in the TNFα-induced canonical NFκB pathway, cIAPs are 
required for non-degradative ubiquitination of the receptor interacting protein 1 (RIP1), 
which induces NFκB activation. In contrast, cIAPs impede the non-canonical NFκB 
activation through the constitutive degradation of the NFκB-inducing kinase (NIK).133 
Furthermore, IAPs were described as signal transducers in the innate immune response 
after activation of pattern recognition receptors (PPRs). Recognition of pathogen-
associated molecular patterns (PAMPs), like e.g. bacterial lipopolysaccharides (LPS), or 
endogenous danger-associated molecular patterns (DAMPs) by PPRs induces an 
inflammatory cell response.134 Analogously to TNFR signaling, IAPs regulate ubiquitin-
dependent signaling processes downstream of the activation of important PPRs (such as 
toll-like receptor 4, NOD-like receptor (NLR) 1/2 or RIG-1), which again culminate in the 
activation of NFκB and MAPKs.91 Interestingly, a subset of intracellular PPRs, the NLRs, 
can activate the inflammasome in macrophages and neutrophils upon PAMP or DAMP 
exposition.135 The inflammasome, a multimeric protein complex, leads to the activation of 
the pro-inflammatory caspase-1, which converts pro-IL-1β into mature IL-1β, a potent 
inflammatory cytokine.136 Although the process of caspase-1 activation is not understood 
in detail, IAPs seem to be critical modulators of the inflammasome assembly. It was 
recently demonstrated that cIAP1 and cIAP2 are effectors of the inflammasome and, thus, 
required for an efficient caspase-1 activation.137 Moreover, the study underlines the anti-
inflammatory potential of IAP antagonists, as the inflammasome response in an 
experimental model of peritonitis was suppressed. In contrast to the observation that IAPs 
promote the inflammatory response, Vince et al. reported that IAPs limit the IL-1β 
activation. Inhibition or depletion of IAPs triggered the inflammasome-dependent cleavage 
of IL-1β. In conclusion, the role of IAPs in leukocyte activation needs further examinations. 
Even though the endothelium functions as multifaceted regulator of the inflammatory 
response, the knowledge about the function of IAPs in endothelial cells is still very limited. 
So far it is known that IAPs positively regulate the production of TNFα-induced cytokines 
and chemokines (e.g. IL-6, -8, GM-CSF, MCP-1, CXCL-1), thus triggering the 
inflammatory response. Indeed, IAP antagonists diminished the TNFα-induced expression 
of these inflammatory mediators in HUVECs.138 Moreover, the inhibition of IAPs was 
reported to block TNFα-evoked vascular inflammation by suppressing the activation of 
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endothelial cells, without sensitizing them to apoptosis.139 Our group revealed that 
treatment with an IAP antagonist prevents leukocyte recruitment to the site of 
inflammation in vivo.4 Further in vitro experiments showed a decreased expression of the 
intercellular adhesion molecule (ICAM)-1 through impaired TNFR signaling and a reduced 
MAPK activation upon loss of IAPs. 
4.2.1 A novel role for IAPs as regulators of the thrombin-induced 
endothelial hyperpermeability 
Besides TNFα, the serine protease thrombin is also a pivotal mediator of the inflammatory 
response. In addition to its central role in the coagulation cascade, thrombin triggers 
distinct signaling pathways in vascular cells: in the endothelium, thrombin induces 
characteristic phenotypic changes, including increased permeability, morphological 
alterations and elevated leukocyte trafficking.140 Thrombin is endogenously produced on 
the surface of injured endothelial cells,114 and, for instance, found at elevated levels in 
severe lung disorders (ALI, ARDS) or atherosclerosis.141-143 In endothelial cells, activation 
of the predominantly expressed thrombin receptor PAR-1 induces a massive dysfunction 
of the endothelial barrier.144, 145 This activation is mediated either through cleavage of the 
receptor’s extracellular N-terminus and consequent exposure of a new N-terminal motif 
(by thrombin) or simply by mimicking this unmasked tethered ligand with a small peptide 
(by TRAP).21, 140  
In the present study, we for the first time elucidate the role of IAPs in the context of pro-
inflammatory thrombin signaling. Herein, we show that inhibition of IAPs prevents the 
typical thrombin-caused endothelial barrier disruption. 
4.2.1.1 IAP antagonists prevent endothelial barrier dysfunction in functional 
assays and the underlying molecular events 
We could demonstrate that two structurally different IAP antagonists (ABT, Smac085) 
significantly reduce TRAP-mediated endothelial hyperpermeability, as assessed with two 
commonly accepted functional permeability assays (measurement of macromolecular 
permeability and TEER). The TRAP-induced flux of the labeled tracer molecule 
(FITC-dextran, 40 kDa) was decreased by both IAP antagonists at any observed time 
point, but most explicit at the latest time point due to the cumulative nature of this method. 
Complementary, the real-time measurement of TEER revealed that IAP antagonism 
protected against the initial and maximal effect of TRAP and, moreover, promoted the 
subsequent recovery of the endothelial barrier.  
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We aimed at explaining the observed barrier protective effects of IAP inhibition on a 
molecular level through analysis of key parameters of endothelial barrier function: 
activation of the contractile machinery (phosphorylation of MLC2), actin remodeling 
(stress fiber formation) and disassembly of AJs (phosphorylation of VE-cadherin). Well 
matching to the observation in the functional assays, ABT positively affected all three 
molecular determinants. The rapid thrombin-evoked stress fiber formation (analyzed after 
5 min), as well as the phosphorylation events of MLC2 (after 5 and 15 min), were 
suppressed by IAP inhibition. Additionally, ABT stabilizes AJs via the decreased 
phosphorylation of VE-cadherin (after 15 and 30 min). Noteworthy, disruption of AJs might 
not only occur after phosphorylation of junctional proteins, but also directly via acto-
myosin driven cellular retraction.18 This explains why we found early barrier stabilizing 
effects of ABT in functional assays, but detected a decrease of VE-cadherin 
phosphorylation only after 15 min. Interestingly, the phosphorylation of VE-cadherin is 
required for successful leukocyte diapedesis.146 Hence, our data confirms previous in vivo 
experiments from Mayer et al., which demonstrated that ABT inhibits leukocyte 
transmigration.4 
4.2.1.2 Unraveling the underlying signaling events 
The role of IAPs in TNFR-signaling is well understood, but their contribution in PAR-
signaling is completely unknown. Both signaling pathways are able to induce the cellular 
stress response in form of enhanced MAPK activity. Our previous study showed that ABT 
suppressed the TNFα-mediated activation of p38 and JNK.4 In contrast, ABT does not 
affect the thrombin-caused activation of the permeability-regulating MAPKs (p38, ERK, 
JNK). ABT neither influenced the typical thrombin-caused rise in [Ca2+]i, nor the activation 
of distinct PKCs. 
Knowing that RhoA is a major regulator of stress fiber formation,147 and due to the fact 
that ABT circumvented the thrombin-induced cytoskeletal remodeling, we hypothesized 
that IAPs might be crucially involved in RhoA signaling.  
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4.2.2 IAPs as regulators of RhoA signaling 
In our study, we demonstrate for the first time that IAPs are indispensable for the full 
RhoA activation in response to thrombin. Both, the genetic depletion and the 
pharmacological inhibition of IAPs abrogated the induced activation of the barrier 
disruption-mediating small GTPase RhoA as well as the subsequent stress fiber 
formation. However, the activity of the counter-regulating GTPase Rac1 was not altered 
upon IAP inhibition. Beyond that, we identified IAPs as unknown binding partners of 
RhoA. 
4.2.2.1 The role of individual IAPs 
The initial characterization of IAP expression in HUVECs revealed that thrombin does not 
alter the respective protein amount. Surprisingly, cIAP2 was not present in our setting 
and, therefore, excluded from further considerations. This can be explained by the 
structural properties of cIAP2: Recently, cIAP2 was found as stable dimer with a high 
intrinsic activity of the E3 ligase domain, thus triggering its permanent auto-ubiquitination 
and subsequent degradation.86  
In order to further elucidate the role of individual IAP family members, we performed 
affinity precipitation experiments and immunocytological stainings of the contractile 
machinery after depletion of either XIAP or cIAP1. Most importantly, we revealed that the 
TRAP-caused RhoA activation and the subsequent cytoskeletal activation depend rather 
on XIAP than cIAP1. Only gene silencing of XIAP is able to induce the same phenotypic 
changes as treatment with an IAP antagonist. At first sight, this is astonishing, since IAP 
antagonists induce the rapid degradation of cIAP1, whereas the levels of XIAP remain 
unaltered.76, 148 IAP antagonists activate the E3 ligase activity of cIAP1 by promoting RING 
dimerization, which, in turn, induces its proteasomal degradation.86 In contrast to this 
observation, the RING activity of XIAP is per se not altered by IAP inhibitors.149 
Nevertheless, the Smac mimetic ABT was designed and evaluated as potent inhibitor of 
XIAP by binding its BIR3 domain in a nanomolar range.88 Altogether, this suggests that 
either the complete loss of XIAP or at least blocking its BIR3 domain is required for the 
prevention of RhoA activation, whereas the loss of cIAP1 seems to be irrelevant.  
Interestingly, we recently could demonstrate that rather cIAP1 than XIAP is predominantly 
responsible for the TNFα-induced ICAM-1 expression.4 This provides evidence that IAP 
family members exert different functions in the endothelium and, therefore, are not 
compensable. 
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4.2.2.2 Interaction of IAPs and small GTPases 
Furthermore, we found a direct interaction of XIAP and RhoA, which appeared to be 
independent of the RhoA nucleotide loading, e.g. the activation state. Until now, an 
association of IAPs with Rho GTPases has only been described for Rac1.74 For example, 
in fruit flies, the IAP homologue Drosophila IAP1 (DIAP1) was shown to affect cell 
migration through an interaction with Rac1, notably also independent of its activity.150 An 
exciting study from the Rajalingam group reported for MEFs and HeLa cells that IAPs 
directly bind GTP- and GDP-loaded Rac1 before initiating its proteasomal degradation.103 
Therefore, one might hypothesize a conserved mechanism behind the binding of IAPs to 
small GTPases, independently of their activation status. As cIAP1, XIAP and DIAP1 share 
the appearance of BIR and RING domains, further investigations are needed to 
characterize the molecular interaction with members of the small GTPases family. 
Moreover, the Rajalingam study highlighted that cIAP1 and XIAP not only bind to Rac1, 
but additionally act as direct E3 ligases for Rac1 poly-ubiquitination and degradation.103 In 
consequence, IAP inhibition led to an increased Rac1 activity and an enhanced cell 
migration. They also showed that RhoA is regulated by IAPs, since the basal activity of 
RhoA was suppressed by an IAP antagonist, although this effect was not subject of further 
investigations. In accordance to that study, our data demonstrate that in the human 
endothelium RhoA activity (induced by thrombin or RhoA overexpression) is controlled by 
IAPs, especially XIAP. In contrast, however, Rac1 is not regulated by IAPs in endothelial 
cells. 
4.2.2.3 IAPs as possible upstream regulators of RhoA activity 
Further studies are needed to identify possible upstream targets of RhoA signaling after 
IAP inhibition and the exact mechanism behind the involvement of XIAP. We might 
speculate that XIAP could directly target RhoA like Smurf1, an E3 ligase known to be an 
upstream mediator of RhoA-ROCK-MLC2 signaling.151 Notably, gene silencing of Smurf1 
in HEK 293T cells induced a cortical actin arrangement, a phenotype similar to our 
observations after XIAP silencing.152 
Moreover, IAP inhibition could also modulate typical upstream regulators of RhoA activity, 
such as GEFs, GAPs or GDIs. Although the knowledge in this field is very limited, a study 
in cancer cells revealed that XIAP binds to RhoGDI, thus decreasing RhoGDI activity, 
which in turn enhances actin polymerization and cell motility.153 One might speculate that 
XIAP inhibition could enforce RhoGDI activity and thereby limit RhoA activity in our 
system. IAPs could also possibly enhance the binding of GEFs to RhoA or alter the 
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interaction with GAPs. Although a role for IAPs in the regulation of GEFs and GAPs is 
currently not described, other E3 ligases are known to affect GEF and GAP activity.154 For 
example, Smurf1, in addition to RhoA, was found to ubiquitinate hPEM-2, a Cdc42 GEF, 
thus affecting cellular migration.155 Furthermore, the activation of RhoA is modulated by 
ubiquitination events of LARG, which represents an important RhoA GEF.156 
4.2.3 Conclusion 
We provided evidence that IAPs, especially XIAP, are important (patho-)physiological 
modulators of endothelial permeability by interfering with RhoA activation. In addition to 
the existing literature on XIAP in the immune regulation, this represents a novel role for 
XIAP as positive regulator of the inflammatory response. Moreover, we introduced IAP 
antagonism as promising pharmacological approach for the prevention of endothelial 
hyperpermeability.  
As small molecule IAP inhibitors are not detrimental to normal tissue and proven to be 
well tolerated in the human organism,157 it would be interesting to pursue our scientific 
findings in preclinical and clinical studies.  
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4.3 Analysis of the endothelial barrier function in vitro 
As we have seen in the first part, in vitro assays for the measurement of the endothelial 
barrier function are indispensable for the identification and characterization of new 
pharmacological targets. Even though in vitro models do not reflect the complexe 
structure of the microvasculature (including pericytes, smooth muscle cells, ECM) and, 
therefore, overestimate the permeability compared to the situation in vivo,158, 159 the use of 
these simplified models enables a precise control of experimental conditions for the 
detailed analysis of potential targets and the underlying signaling events. 
In this work, we for the first time investigated the individual advantages and limitations of 
two widely used in vitro methods for the analysis of the endothelial barrier function: the 
well-established measurement of macromolecular permeability with a Transwell® two-
compartment system and a modern impedance sensing device (xCELLigence™). 
Therefore, we tested different established barrier-modulating compounds in both 
permeability assays and compared the results to alterations of the F-actin cytoskeleton 
and the activation of the contractile machinery as universal indicators of endothelial 
integrity. 
4.3.1 Comparing the results from macromolecular permeability 
measurement and impedance sensing 
Given that two different types of analysis parameters, flux of macromolecules and cellular 
impedance, are utilized for the characterization of barrier properties, it is not surprising 
that not always congruent observations were made.  
The biophysical dimension impedance provides information about morphological 
properties of cells.54 Altered cell-cell contacts and cell-substratum interactions influence 
the ion conducting properties of a cell layer. This presents a rather artificial readout 
parameter as mainly the permeability of small ions is evaluated. In contrast, the real flux of 
macromolecules across the cellular barrier mimics the physiological function of the 
endothelium in vivo.13 Nevertheless, the defined pore size of the filter as well as the 
homogenous weight of the added tracer molecule differs from the physiological situation.  
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4.3.1.1 Congruent results in both permeability assays after forskolin treatment 
Our results for the treatment of HMECs with the barrier enhancer forskolin prior to TRAP 
addition confirm the applicability of MP and as well as impedance measurement as 
general indicators for endothelial permeability. As proof of concept, we showed that 
forskolin abrogates the activation of MLC2 and inhibited stress fiber formation. In 
accordance to our observations in the endothelium, Wegener et al. demonstrated barrier 
protective properties of forskolin in porcine brain epithelial cells in all major in vitro 
permeability assays (MP, TEER and impedance).160 Interestingly, a theoretical model of 
the performed impedance analysis revealed that the barrier protective effects of forskolin 
were partially caused by cell-substratum reinforcement and not only from strengthening of 
IEJs. As this discrimination is not feasible with MP or TEER measurement, the possibility 
to mathematically re-evaluate impedance data represents an advantage for the advanced 
user of impedance-based assays. 
4.3.1.2 The use of histamine reveals the limitations of macromolecular 
permeability measurement 
The rapid and transient histamine-induced permeability response can be monitored in 
real-time by impedance sensing, whereas the cumulative MP method is lacking sensitivity, 
which caused huge standard errors and no clear correlation between the applied 
concentrations and the measured effects. Our impedance data are perfectly matching to 
the time points of MLC2 activation found in the literature. The maximum phosphorylation 
of MLC2 occurs after 30 s, persists for 90 s and then returns to base level after 5 min.43 
Impedance values immediately drop upon histamine exposure, reach the maximum 
decline after about 1 min and are drawn back to basal conditions after 5 min latest. 
Surprisingly, histamine does not only decrease endothelial barrier function by a transient 
disruption of cell-cell contacts, but subsequently enhances barrier properties, partly 
through the restoration of intercellular adhesions, and mainly through an increasing cell-
matrix interaction.161 These effects are displayed by impedance sensing, as we detect a 
drop of impedance values within minutes and a subsequent increase above control levels. 
This dual nature of the histamine effect is masked in MP measurement, as only an 
increase of FITC-dextran passage is detectable.  
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4.3.1.3 ROCK inhibition increases basal permeability, but clearly prevents TRAP-
induced barrier disruption 
The results from both permeability assays indicated that inhibition of ROCK with Y-27632 
elevates endothelial permeability under basal conditions, but protects against TRAP-
induced barrier dysfunction. Obviously, ROCK has opposing activities in the regulation of 
the endothelial barrier function: it shows intrinsic barrier protective properties at cell 
margins and an inducible barrier-disruptive activity at F-actin stress fibers.162 Treatment of 
HMECs with Y-27632 alone moderately elevates the flux of macromolecules, whereas a 
massive drop of impedance values is detected. Even though the phosphorylation of MLC2 
is completely suppressed by Y-27632, ROCK inhibition considerably alters the F-actin 
morphology, which might be the cause for the elevated macromolecular permeability and 
the dramatic impedance decline. Our results and findings from others indicate that the 
interpretation Western blot results might be misleading without further permeability 
assays, as Y-27632 increases basal permeability despite a decreased activation of 
MLC2.163 In contrast, ROCK inhibition clearly prevented the TRAP-induced flux of 
macromolecules across the cell layer and, furthermore, reduced the TRAP-evoked 
impedance drop. Here, both observations correlate with the suppression of MLC2 activity 
and the suppression of stress fiber assembly. 
4.3.1.4 Blebbistatin evokes controversial responses in both permeability assays 
Treatment with blebbistatin shows contradictory results in both permeability assays as it 
dramatically affects impedance sensing, whereas macromolecular permeability is not 
altered at all. Blebbistatin is known to abolish the cellular tension as it inhibits the 
myosin II binding to actin.122 Cellular morphology is mainly controlled by two opposing 
systems: intercellular adhesion and cellular tension.164 Obviously, blebbistatin treatment 
alters the cell shape only via the decrease of intracellular tension, as it does not affect the 
composition of adherens junctions.165 Notably, the thrombin-induced phosphorylation of 
MLC2 and the F-actin polymerization is not influenced by blebbistatin.122 We, therefore, 
conclude that impedance sensing displays mainly blebbistatin-mediated cell morphology 
changes caused by a decreased cellular tension, whereas the permeability of 
macromolecules is not affected as intercellular adhesions are not influenced by 
blebbistatin.  
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4.3.2 Conclusion 
Real-time impedance measurement is a highly sensitive and label-free method to monitor 
cell morphology changes. Alterations of the endothelial barrier function are associated 
with such morphological changes. This is reflected by different ion fluxes in impedance 
measurement and by macromolecular fluxes in the Transwell® assay.  
However, morphological changes are not exclusively related to the endothelial barrier. We 
found that impedance data only partially correlated with permeability and, moreover, was 
not always easy to interpret. Therefore, we suggest utilizing it as complementary tool to 
acquire further information about the barrier characteristics. For example, real-time 
monitoring of impedance allows the determination of the ideal time point for the 
examination of the cytoskeleton or to perform macromolecular permeability measurement. 
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The vascular endothelium represents an attractive drug target system for the development 
of new anti-inflammatory strategies, as it regulates the extravasation of leukocytes, 
solutes and plasma proteins due to its barrier function. Dysfunction of the endothelial 
barrier is a key feature of many severe diseases with an inflammatory component, such 
as sepsis, ALI or atherosclerosis. As drugs that specifically target endothelial barrier-
regulating systems are widely lacking, there is a strong demand for the identification of 
pharmacological targets. Therefore, sensitive and reliable methods for the analysis of the 
endothelial barrier function are indispensable. 
First, we could identify IAPs as crucial regulators of the thrombin-induced inflammatory 
response by mediating RhoA activation, which evokes endothelial hyperpermeability. We 
furthermore revealed that IAP antagonists prevent endothelial barrier dysfunction, stabilize 
AJs, suppress cellular contraction and inhibit stress fiber formation independently of Ca2+, 
PKC or MAPK signaling pathways. Interestingly, RhoA activation and the subsequent 
downstream events (stress fiber assembly, activation of the contractile machinery) were 
blocked by IAP inhibition or specific gene knockdown of XIAP. Additionally, a direct 
interaction of XIAP and RhoA was reported, which occurred irrespective of the RhoA 
activation status.  
In conclusion, we found a new function for IAPs (especially XIAP) as positive regulators of 
inflammatory processes (i.e. the regulation of the endothelial barrier function) extending 
the existing knowledge on IAPs in the immune regulation. In consequence, IAP 
antagonism represents a promising approach for the treatment of hyperpermeability-
associated disorders. 
Secondly, we for the first time compared the conventional macromolecular permeability 
measurement (with a Transwell® two-compartment system) with the modern impedance 
sensing (with a xCELLigence™ RTCA analyzer) as methods for the analysis of the 
endothelial barrier function. Therefore, we studied the effects of different well established 
barrier-modulating compounds in both permeability assays and compared the results to 
alterations of the F-actin cytoskeleton and the activation of motor proteins (MLC2). 
Altogether, impedance sensing is a highly sensitive method with an extraordinary time 
resolution for the detection cell morphology changes, which, however, do not necessarily 
correlate with permeability changes. In contrast, the Transwell® system, which depicts the 
real flux of macromolecules across a cell layer, has limitations in terms of sensitivity and 
time resolution. Consequently, we recommend the complementary use of both methods 
and to reconsider their individual limitations, since each technique alone can not fully 
determine all consequences of barrier-modulating compounds. 
 
6 REFERENCES 
  
6  REFERENCES 93 
1. Yuan, S.Y. & Rigor, R.R. in Regulation of Endothelial Barrier Function (San Rafael 
(CA), 2010). 
2. Fulda, S. & Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. 
Nat Rev Drug Discov 11, 109-24 (2012). 
3. Gyrd-Hansen, M. & Meier, P. IAPs: from caspase inhibitors to modulators of NF-
kappaB, inflammation and cancer. Nat Rev Cancer 10, 561-74 (2010). 
4. Mayer, B.A. et al. Inhibitor of apoptosis proteins as novel targets in inflammatory 
processes. Arterioscler Thromb Vasc Biol 31, 2240-50 (2011). 
5. Aird, W.C. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 
3, 1392-406 (2005). 
6. Cooke, J.P. The endothelium: a new target for therapy. Vasc Med 5, 49-53 (2000). 
7. Feletou, M. in The Endothelium: Part 1: Multiple Functions of the Endothelial Cells-
Focus on Endothelium-Derived Vasoactive Mediators (San Rafael (CA), 2011). 
8. Scallan, J., Huxley, V.H. & Korthuis, R.J. in Capillary Fluid Exchange: Regulation, 
Functions, and Pathology (San Rafael (CA), 2010). 
9. Peterson, K. et al. in Drug Class Review: Nonsteroidal Antiinflammatory Drugs 
(NSAIDs): Final Update 4 Report (Portland (OR), 2010). 
10. Rhen, T. & Cidlowski, J.A. Antiinflammatory action of glucocorticoids--new 
mechanisms for old drugs. N Engl J Med 353, 1711-23 (2005). 
11. Foley, J.F. Focus issue: understanding mechanisms of inflammation. Sci Signal 6, 
eg2 (2013). 
12. van Nieuw Amerongen, G.P. & van Hinsbergh, V.W. Targets for pharmacological 
intervention of endothelial hyperpermeability and barrier function. Vascul 
Pharmacol 39, 257-72 (2002). 
13. Komarova, Y. & Malik, A.B. Regulation of endothelial permeability via paracellular 
and transcellular transport pathways. Annu Rev Physiol 72, 463-93 (2010). 
14. Minshall, R.D., Sessa, W.C., Stan, R.V., Anderson, R.G. & Malik, A.B. Caveolin 
regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 285, L1179-
83 (2003). 
15. Vandenbroucke, E., Mehta, D., Minshall, R. & Malik, A.B. Regulation of endothelial 
junctional permeability. Ann N Y Acad Sci 1123, 134-45 (2008). 
16. Mehta, D. & Malik, A.B. Signaling mechanisms regulating endothelial permeability. 
Physiol Rev 86, 279-367 (2006). 
17. Goldblum, S.E., Ding, X. & Campbell-Washington, J. TNF-alpha induces 
endothelial cell F-actin depolymerization, new actin synthesis, and barrier 
dysfunction. Am J Physiol 264, C894-905 (1993). 
18. Dejana, E., Orsenigo, F. & Lampugnani, M.G. The role of adherens junctions and 
VE-cadherin in the control of vascular permeability. J Cell Sci 121, 2115-22 (2008). 
19. Shen, Q., Wu, M.H. & Yuan, S.Y. Endothelial contractile cytoskeleton and 
microvascular permeability. Cell Health Cytoskelet 2009, 43-50 (2009). 
20. van Hinsbergh, V.W. & van Nieuw Amerongen, G.P. Intracellular signalling 
involved in modulating human endothelial barrier function. J Anat 200, 549-60 
(2002). 
21. Cirino, G. et al. Thrombin functions as an inflammatory mediator through activation 
of its receptor. J Exp Med 183, 821-7 (1996). 
22. Gerszten, R.E. et al. Specificity of the thrombin receptor for agonist peptide is 
defined by its extracellular surface. Nature 368, 648-51 (1994). 
23. Kumar, P. et al. Molecular mechanisms of endothelial hyperpermeability: 
implications in inflammation. Expert Rev Mol Med 11, e19 (2009). 
24. Ahmmed, G.U. & Malik, A.B. Functional role of TRPC channels in the regulation of 
endothelial permeability. Pflugers Arch 451, 131-42 (2005). 
25. Smyth, J.T. et al. Activation and regulation of store-operated calcium entry. J Cell 
Mol Med 14, 2337-49 (2010). 
6  REFERENCES 94 
26. Dudek, S.M. & Garcia, J.G. Cytoskeletal regulation of pulmonary vascular 
permeability. J Appl Physiol 91, 1487-500 (2001). 
27. Shen, Q., Rigor, R.R., Pivetti, C.D., Wu, M.H. & Yuan, S.Y. Myosin light chain 
kinase in microvascular endothelial barrier function. Cardiovasc Res 87, 272-80 
(2010). 
28. Lum, H. & Malik, A.B. Mechanisms of increased endothelial permeability. Can J 
Physiol Pharmacol 74, 787-800 (1996). 
29. Rigor, R.R., Shen, Q., Pivetti, C.D., Wu, M.H. & Yuan, S.Y. Myosin light chain 
kinase signaling in endothelial barrier dysfunction. Med Res Rev 33, 911-33 
(2013). 
30. Garcia, J.G., Davis, H.W. & Patterson, C.E. Regulation of endothelial cell gap 
formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell 
Physiol 163, 510-22 (1995). 
31. Sandoval, R. et al. Ca(2+) signalling and PKCalpha activate increased endothelial 
permeability by disassembly of VE-cadherin junctions. J Physiol 533, 433-45 
(2001). 
32. Borbiev, T. et al. Role of CaM kinase II and ERK activation in thrombin-induced 
endothelial cell barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 285, L43-
54 (2003). 
33. Borbiev, T. et al. p38 MAP kinase-dependent regulation of endothelial cell 
permeability. Am J Physiol Lung Cell Mol Physiol 287, L911-8 (2004). 
34. Kiemer, A.K. et al. Inhibition of p38 MAPK activation via induction of MKP-1: atrial 
natriuretic peptide reduces TNF-alpha-induced actin polymerization and 
endothelial permeability. Circ Res 90, 874-81 (2002). 
35. Arndt, P.G. et al. Inhibition of c-Jun N-terminal kinase limits lipopolysaccharide-
induced pulmonary neutrophil influx. Am J Respir Crit Care Med 171, 978-86 
(2005). 
36. Yuan, S.Y. Protein kinase signaling in the modulation of microvascular 
permeability. Vascul Pharmacol 39, 213-23 (2002). 
37. Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629-35 
(2002). 
38. Hall, A. & Nobes, C.D. Rho GTPases: molecular switches that control the 
organization and dynamics of the actin cytoskeleton. Philos Trans R Soc Lond B 
Biol Sci 355, 965-70 (2000). 
39. Spindler, V., Schlegel, N. & Waschke, J. Role of GTPases in control of 
microvascular permeability. Cardiovasc Res 87, 243-53 (2010). 
40. van Nieuw Amerongen, G.P., van Delft, S., Vermeer, M.A., Collard, J.G. & van 
Hinsbergh, V.W. Activation of RhoA by thrombin in endothelial hyperpermeability: 
role of Rho kinase and protein tyrosine kinases. Circ Res 87, 335-40 (2000). 
41. Gainor, J.P., Morton, C.A., Bell, D.R., Vincent, P.A. & Minnear, F.L. Platelet 
phospholipids decrease vascular endothelial permeability via a novel signaling 
pathway independent of cAMP/protein kinase A. Ann N Y Acad Sci 905, 315-8 
(2000). 
42. Perez-Moreno, M., Jamora, C. & Fuchs, E. Sticky business: orchestrating cellular 
signals at adherens junctions. Cell 112, 535-48 (2003). 
43. Moy, A.B., Shasby, S.S., Scott, B.D. & Shasby, D.M. The effect of histamine and 
cyclic adenosine monophosphate on myosin light chain phosphorylation in human 
umbilical vein endothelial cells. J Clin Invest 92, 1198-206 (1993). 
44. Langeler, E.G. & van Hinsbergh, V.W. Norepinephrine and iloprost improve barrier 
function of human endothelial cell monolayers: role of cAMP. Am J Physiol 260, 
C1052-9 (1991). 
45. Kooistra, M.R., Corada, M., Dejana, E. & Bos, J.L. Epac1 regulates integrity of 
endothelial cell junctions through VE-cadherin. FEBS Lett 579, 4966-72 (2005). 
6  REFERENCES 95 
46. Birukova, A.A. et al. Rac GTPase is a hub for protein kinase A and Epac signaling 
in endothelial barrier protection by cAMP. Microvasc Res 79, 128-38 (2010). 
47. Wojciak-Stothard, B. & Ridley, A.J. Rho GTPases and the regulation of endothelial 
permeability. Vascul Pharmacol 39, 187-99 (2002). 
48. Miles, A.A. & Miles, E.M. Vascular reactions to histamine, histamine-liberator and 
leukotaxine in the skin of guinea-pigs. J Physiol 118, 228-57 (1952). 
49. Ley, K. & Arfors, K.E. Segmental differences of microvascular permeability for 
FITC-dextrans measured in the hamster cheek pouch. Microvasc Res 31, 84-99 
(1986). 
50. Giaever, I. & Keese, C.R. A morphological biosensor for mammalian cells. Nature 
366, 591-2 (1993). 
51. Siflinger-Birnboim, A. et al. Molecular sieving characteristics of the cultured 
endothelial monolayer. J Cell Physiol 132, 111-7 (1987). 
52. Ehringer, W.D., Wang, O.L., Haq, A. & Miller, F.N. Bradykinin and alpha-thrombin 
increase human umbilical vein endothelial macromolecular permeability by 
different mechanisms. Inflammation 24, 175-93 (2000). 
53. Giaever, I. & Keese, C.R. Micromotion of mammalian cells measured electrically. 
Proc Natl Acad Sci U S A 88, 7896-900 (1991). 
54. Yu, N. et al. Real-time monitoring of morphological changes in living cells by 
electronic cell sensor arrays: an approach to study G protein-coupled receptors. 
Anal Chem 78, 35-43 (2006). 
55. Xiao, C. & Luong, J.H. On-line monitoring of cell growth and cytotoxicity using 
electric cell-substrate impedance sensing (ECIS). Biotechnol Prog 19, 1000-5 
(2003). 
56. Xiao, C., Lachance, B., Sunahara, G. & Luong, J.H. An in-depth analysis of electric 
cell-substrate impedance sensing to study the attachment and spreading of 
mammalian cells. Anal Chem 74, 1333-9 (2002). 
57. Lo, C.M., Keese, C.R. & Giaever, I. Monitoring motion of confluent cells in tissue 
culture. Exp Cell Res 204, 102-9 (1993). 
58. Stolwijk, J.A. et al. Impedance analysis of adherent cells after in situ 
electroporation: non-invasive monitoring during intracellular manipulations. 
Biosens Bioelectron 26, 4720-7 (2011). 
59. Opp, D. et al. Use of electric cell-substrate impedance sensing to assess in vitro 
cytotoxicity. Biosens Bioelectron 24, 2625-9 (2009). 
60. Bagnaninchi, P.O. & Drummond, N. Real-time label-free monitoring of adipose-
derived stem cell differentiation with electric cell-substrate impedance sensing. 
Proc Natl Acad Sci U S A 108, 6462-7 (2011). 
61. Hsu, C.C., Tsai, W.C., Chen, C.P., Lu, Y.M. & Wang, J.S. Effects of negative 
pressures on epithelial tight junctions and migration in wound healing. Am J 
Physiol Cell Physiol 299, C528-34 (2010). 
62. Wang, H.S., Keese, C.R., Giaever, I. & Smith, T.J. Prostaglandin E2 alters human 
orbital fibroblast shape through a mechanism involving the generation of cyclic 
adenosine monophosphate. J Clin Endocrinol Metab 80, 3553-60 (1995). 
63. Tiruppathi, C., Malik, A.B., Del Vecchio, P.J., Keese, C.R. & Giaever, I. Electrical 
method for detection of endothelial cell shape change in real time: assessment of 
endothelial barrier function. Proc Natl Acad Sci U S A 89, 7919-23 (1992). 
64. Dubrez-Daloz, L., Dupoux, A. & Cartier, J. IAPs: more than just inhibitors of 
apoptosis proteins. Cell Cycle 7, 1036-46 (2008). 
65. Srinivasula, S.M. & Ashwell, J.D. IAPs: what's in a name? Mol Cell 30, 123-35 
(2008). 
66. Crook, N.E., Clem, R.J. & Miller, L.K. An apoptosis-inhibiting baculovirus gene with 
a zinc finger-like motif. J Virol 67, 2168-74 (1993). 
6  REFERENCES 96 
67. Uren, A.G., Coulson, E.J. & Vaux, D.L. Conservation of baculovirus inhibitor of 
apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. 
Trends Biochem Sci 23, 159-62 (1998). 
68. Eckelman, B.P., Salvesen, G.S. & Scott, F.L. Human inhibitor of apoptosis 
proteins: why XIAP is the black sheep of the family. EMBO Rep 7, 988-94 (2006). 
69. Mace, P.D., Shirley, S. & Day, C.L. Assembling the building blocks: structure and 
function of inhibitor of apoptosis proteins. Cell Death Differ 17, 46-53 (2010). 
70. Eckelman, B.P. & Salvesen, G.S. The human anti-apoptotic proteins cIAP1 and 
cIAP2 bind but do not inhibit caspases. J Biol Chem 281, 3254-60 (2006). 
71. Bertrand, M.J. & Vandenabeele, P. The Ripoptosome: death decision in the 
cytosol. Mol Cell 43, 323-5 (2011). 
72. Varfolomeev, E., Wayson, S.M., Dixit, V.M., Fairbrother, W.J. & Vucic, D. The 
inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB 
activation independently of TRAF1 AND TRAF2. J Biol Chem 281, 29022-9 
(2006). 
73. Fulda, S., Rajalingam, K. & Dikic, I. Ubiquitylation in immune disorders and cancer: 
from molecular mechanisms to therapeutic implications. EMBO Mol Med 4, 545-56 
(2012). 
74. Oberoi-Khanuja, T.K. & Rajalingam, K. IAPs as E3 ligases of Rac1: shaping the 
move. Small GTPases 3, 131-6 (2012). 
75. MacFarlane, M., Merrison, W., Bratton, S.B. & Cohen, G.M. Proteasome-mediated 
degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. 
J Biol Chem 277, 36611-6 (2002). 
76. Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-
kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-81 (2007). 
77. Xu, P. et al. Quantitative proteomics reveals the function of unconventional 
ubiquitin chains in proteasomal degradation. Cell 137, 133-45 (2009). 
78. Lopez, J. & Meier, P. To fight or die - inhibitor of apoptosis proteins at the 
crossroad of innate immunity and death. Curr Opin Cell Biol 22, 872-81 (2010). 
79. Gyrd-Hansen, M. et al. IAPs contain an evolutionarily conserved ubiquitin-binding 
domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat 
Cell Biol 10, 1309-17 (2008). 
80. Lopez, J. et al. CARD-mediated autoinhibition of cIAP1's E3 ligase activity 
suppresses cell proliferation and migration. Mol Cell 42, 569-83 (2011). 
81. Fulda, S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in 
hematological malignancies. Leukemia 26, 1155-65 (2012). 
82. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that 
promotes cytochrome c-dependent caspase activation by eliminating IAP 
inhibition. Cell 102, 33-42 (2000). 
83. Chai, J. et al. Structural and biochemical basis of apoptotic activation by 
Smac/DIABLO. Nature 406, 855-62 (2000). 
84. Vucic, D. & Fairbrother, W.J. The inhibitor of apoptosis proteins as therapeutic 
targets in cancer. Clin Cancer Res 13, 5995-6000 (2007). 
85. Vince, J.E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent 
apoptosis. Cell 131, 682-93 (2007). 
86. Feltham, R. et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by 
promoting RING domain dimerization. J Biol Chem 286, 17015-28 (2011). 
87. Liu, Z. et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 
domain. Nature 408, 1004-8 (2000). 
88. Oost, T.K. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP 
for the treatment of cancer. J Med Chem 47, 4417-26 (2004). 
89. de Almagro, M.C. & Vucic, D. The inhibitor of apoptosis (IAP) proteins are critical 
regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 
34, 200-11 (2012). 
6  REFERENCES 97 
90. Flygare, J.A. et al. Discovery of a potent small-molecule antagonist of inhibitor of 
apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-
0152). J Med Chem 55, 4101-13 (2012). 
91. Damgaard, R.B. & Gyrd-Hansen, M. Inhibitor of apoptosis (IAP) proteins in 
regulation of inflammation and innate immunity. Discov Med 11, 221-31 (2011). 
92. Ades, E.W. et al. HMEC-1: establishment of an immortalized human microvascular 
endothelial cell line. J Invest Dermatol 99, 683-90 (1992). 
93. Bouis, D., Hospers, G.A., Meijer, C., Molema, G. & Mulder, N.H. Endothelium in 
vitro: a review of human vascular endothelial cell lines for blood vessel-related 
research. Angiogenesis 4, 91-102 (2001). 
94. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 
248-54 (1976). 
95. Smith, P.K. et al. Measurement of protein using bicinchoninic acid. Anal Biochem 
150, 76-85 (1985). 
96. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-5 (1970). 
97. Kurien, B.T. & Scofield, R.H. Protein blotting: a review. J Immunol Methods 274, 1-
15 (2003). 
98. Furst, R. et al. Atrial natriuretic peptide protects against histamine-induced 
endothelial barrier dysfunction in vivo. Mol Pharmacol 74, 1-8 (2008). 
99. Nagel, W., Somieski, P. & Katz, U. Selective inhibition of Cl(-) conductance in toad 
skin by blockers of Cl(-) channels and transporters. Am J Physiol Cell Physiol 281, 
C1223-32 (2001). 
100. Zamore, P.D. RNA interference: big applause for silencing in Stockholm. Cell 127, 
1083-6 (2006). 
101. Benard, V. & Bokoch, G.M. Assay of Cdc42, Rac, and Rho GTPase activation by 
affinity methods. Methods Enzymol 345, 349-59 (2002). 
102. Ren, X.D. & Schwartz, M.A. Determination of GTP loading on Rho. Methods 
Enzymol 325, 264-72 (2000). 
103. Oberoi, T.K. et al. IAPs regulate the plasticity of cell migration by directly targeting 
Rac1 for degradation. EMBO J 31, 14-28 (2012). 
104. Grynkiewicz, G., Poenie, M. & Tsien, R.Y. A new generation of Ca2+ indicators 
with greatly improved fluorescence properties. J Biol Chem 260, 3440-50 (1985). 
105. Ley, K., Laudanna, C., Cybulsky, M.I. & Nourshargh, S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7, 678-
89 (2007). 
106. Fernandez-Borja, M., van Buul, J.D. & Hordijk, P.L. The regulation of leucocyte 
transendothelial migration by endothelial signalling events. Cardiovasc Res 86, 
202-10 (2010). 
107. Schulte, D. et al. Stabilizing the VE-cadherin-catenin complex blocks leukocyte 
extravasation and vascular permeability. EMBO J 30, 4157-70 (2011). 
108. Lampugnani, M.G. & Dejana, E. Adherens junctions in endothelial cells regulate 
vessel maintenance and angiogenesis. Thromb Res 120 Suppl 2, S1-6 (2007). 
109. Kluger, M.S., Clark, P.R., Tellides, G., Gerke, V. & Pober, J.S. Claudin-5 controls 
intercellular barriers of human dermal microvascular but not human umbilical vein 
endothelial cells. Arterioscler Thromb Vasc Biol 33, 489-500 (2013). 
110. Potter, M.D., Barbero, S. & Cheresh, D.A. Tyrosine phosphorylation of VE-
cadherin prevents binding of p120- and beta-catenin and maintains the cellular 
mesenchymal state. J Biol Chem 280, 31906-12 (2005). 
111. Bogatcheva, N.V. & Verin, A.D. The role of cytoskeleton in the regulation of 
vascular endothelial barrier function. Microvasc Res 76, 202-7 (2008). 
112. Kim, K.M. et al. Molecular characterization of myosin phosphatase in endothelium. 
J Cell Physiol 227, 1701-8 (2012). 
6  REFERENCES 98 
113. Ito, M., Nakano, T., Erdodi, F. & Hartshorne, D.J. Myosin phosphatase: structure, 
regulation and function. Mol Cell Biochem 259, 197-209 (2004). 
114. Bogatcheva, N.V., Garcia, J.G. & Verin, A.D. Molecular mechanisms of thrombin-
induced endothelial cell permeability. Biochemistry (Mosc) 67, 75-84 (2002). 
115. Putney, J.W. Pharmacology of store-operated calcium channels. Mol Interv 10, 
209-18 (2010). 
116. Spiering, D. & Hodgson, L. Dynamics of the Rho-family small GTPases in actin 
regulation and motility. Cell Adh Migr 5, 170-80 (2011). 
117. Moorman, J.P., Luu, D., Wickham, J., Bobak, D.A. & Hahn, C.S. A balance of 
signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates 
cytoskeletal morphology but not cell survival. Oncogene 18, 47-57 (1999). 
118. Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V. & Baldwin, A.S., Jr. NF-
kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to 
suppress caspase-8 activation. Science 281, 1680-3 (1998). 
119. Bubik, M.F. et al. A novel approach to prevent endothelial hyperpermeability: the 
Crataegus extract WS(R) 1442 targets the cAMP/Rap1 pathway. J Mol Cell 
Cardiol 52, 196-205 (2012). 
120. Ludwig, A., Sommer, A. & Uhlig, S. Assessment of endothelial permeability and 
leukocyte transmigration in human endothelial cell monolayers. Methods Mol Biol 
763, 319-32 (2011). 
121. Waschke, J., Drenckhahn, D., Adamson, R.H., Barth, H. & Curry, F.E. cAMP 
protects endothelial barrier functions by preventing Rac-1 inhibition. Am J Physiol 
Heart Circ Physiol 287, H2427-33 (2004). 
122. Goeckeler, Z.M., Bridgman, P.C. & Wysolmerski, R.B. Nonmuscle myosin II is 
responsible for maintaining endothelial cell basal tone and stress fiber integrity. 
Am J Physiol Cell Physiol 295, C994-1006 (2008). 
123. He, P. Leucocyte/endothelium interactions and microvessel permeability: coupled 
or uncoupled? Cardiovasc Res 87, 281-90 (2010). 
124. Kubes, P., Suzuki, M. & Granger, D.N. Modulation of PAF-induced leukocyte 
adherence and increased microvascular permeability. Am J Physiol 259, G859-64 
(1990). 
125. Sumagin, R., Lomakina, E. & Sarelius, I.H. Leukocyte-endothelial cell interactions 
are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol 
Heart Circ Physiol 295, H969-H977 (2008). 
126. Simmons, D.L. Anti-adhesion therapies. Curr Opin Pharmacol 5, 398-404 (2005). 
127. Becker, K.J. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab 
(R6.5) in acute stroke. Curr Med Res Opin 18 Suppl 2, s18-22 (2002). 
128. Phillipson, M., Kaur, J., Colarusso, P., Ballantyne, C.M. & Kubes, P. Endothelial 
domes encapsulate adherent neutrophils and minimize increases in vascular 
permeability in paracellular and transcellular emigration. PLoS One 3, e1649 
(2008). 
129. Zeng, M., Zhang, H., Lowell, C. & He, P. Tumor necrosis factor-alpha-induced 
leukocyte adhesion and microvessel permeability. Am J Physiol Heart Circ Physiol 
283, H2420-30 (2002). 
130. Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF-
kappaB and MAPK activation by members of the TNF family of receptors. Sci 
Signal 5, ra22 (2012). 
131. Shu, H.B., Takeuchi, M. & Goeddel, D.V. The tumor necrosis factor receptor 2 
signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor 
receptor 1 signaling complex. Proc Natl Acad Sci U S A 93, 13973-8 (1996). 
132. Mahoney, D.J. et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-
kappaB activation. Proc Natl Acad Sci U S A 105, 11778-83 (2008). 
133. Vucic, D. TRAF2 and cellular IAPs: a critical link in TNFR family signaling. Adv Exp 
Med Biol 691, 63-78 (2011). 
6  REFERENCES 99 
134. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. 
Cell 124, 783-801 (2006). 
135. Davis, B.K., Wen, H. & Ting, J.P. The inflammasome NLRs in immunity, 
inflammation, and associated diseases. Annu Rev Immunol 29, 707-35 (2011). 
136. Labbe, K. & Saleh, M. Cell death in the host response to infection. Cell Death 
Differ 15, 1339-49 (2008). 
137. Labbe, K., McIntire, C.R., Doiron, K., Leblanc, P.M. & Saleh, M. Cellular inhibitors 
of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 
activation by the inflammasome. Immunity 35, 897-907 (2011). 
138. Kearney, C.J. et al. Inhibitor of Apoptosis Proteins (IAPs) and Their Antagonists 
Regulate Spontaneous and Tumor Necrosis Factor (TNF)-induced 
Proinflammatory Cytokine and Chemokine Production. J Biol Chem 288, 4878-90 
(2013). 
139. Luong le, A. & Evans, P.C. Targeting inhibitor of apoptosis proteins to block 
vascular inflammation. Arterioscler Thromb Vasc Biol 31, 2165-6 (2011). 
140. Minami, T. et al. Thrombin and phenotypic modulation of the endothelium. 
Arterioscler Thromb Vasc Biol 24, 41-53 (2004). 
141. Kipnis, E. et al. Massive alveolar thrombin activation in Pseudomonas aeruginosa-
induced acute lung injury. Shock 21, 444-51 (2004). 
142. Welty-Wolf, K.E., Carraway, M.S., Ortel, T.L. & Piantadosi, C.A. Coagulation and 
inflammation in acute lung injury. Thromb Haemost 88, 17-25 (2002). 
143. Wei, H.J. et al. Thrombomodulin domains attenuate atherosclerosis by inhibiting 
thrombin-induced endothelial cell activation. Cardiovasc Res 92, 317-27 (2011). 
144. Lee, H. & Hamilton, J.R. Physiology, pharmacology, and therapeutic potential of 
protease-activated receptors in vascular disease. Pharmacol Ther 134, 246-59 
(2012). 
145. van Nieuw Amerongen, G.P., Draijer, R., Vermeer, M.A. & van Hinsbergh, V.W. 
Transient and prolonged increase in endothelial permeability induced by histamine 
and thrombin: role of protein kinases, calcium, and RhoA. Circ Res 83, 1115-23 
(1998). 
146. Turowski, P. et al. Phosphorylation of vascular endothelial cadherin controls 
lymphocyte emigration. J Cell Sci 121, 29-37 (2008). 
147. Pellegrin, S. & Mellor, H. Actin stress fibres. J Cell Sci 120, 3491-9 (2007). 
148. Yang, Q.H. & Du, C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-
IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 279, 16963-70 
(2004). 
149. Nakatani, Y. et al. Regulation of ubiquitin transfer by XIAP, a dimeric RING E3 
ligase. Biochem J 450, 629-38 (2013). 
150. Geisbrecht, E.R. & Montell, D.J. A role for Drosophila IAP1-mediated caspase 
inhibition in Rac-dependent cell migration. Cell 118, 111-25 (2004). 
151. Sahai, E., Garcia-Medina, R., Pouyssegur, J. & Vial, E. Smurf1 regulates tumor 
cell plasticity and motility through degradation of RhoA leading to localized 
inhibition of contractility. J Cell Biol 176, 35-42 (2007). 
152. Wang, H.R. et al. Regulation of cell polarity and protrusion formation by targeting 
RhoA for degradation. Science 302, 1775-9 (2003). 
153. Liu, J. et al. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell 
motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the 
cytoskeleton. J Biol Chem 286, 15630-40 (2011). 
154. Ding, F., Yin, Z. & Wang, H.R. Ubiquitination in Rho signaling. Curr Top Med 
Chem 11, 2879-87 (2011). 
155. Yamaguchi, K., Ohara, O., Ando, A. & Nagase, T. Smurf1 directly targets hPEM-2, 
a GEF for Cdc42, via a novel combination of protein interaction modules in the 
ubiquitin-proteasome pathway. Biol Chem 389, 405-13 (2008). 
6  REFERENCES 100 
156. Yang, Y. et al. CYLD regulates RhoA activity by modulating LARG ubiquitination. 
PLoS One 8, e55833 (2013). 
157. Wong, H. et al. Dogs are more sensitive to antagonists of inhibitor of apoptosis 
proteins than rats and humans: a translational toxicokinetic/toxicodynamic 
analysis. Toxicol Sci 130, 205-13 (2012). 
158. Albelda, S.M. et al. Permeability characteristics of cultured endothelial cell 
monolayers. J Appl Physiol 64, 308-22 (1988). 
159. Steinberg, B.E., Goldenberg, N.M. & Lee, W.L. Do viral infections mimic bacterial 
sepsis? The role of microvascular permeability: A review of mechanisms and 
methods. Antiviral Res 93, 2-15 (2012). 
160. Wegener, J., Hakvoort, A. & Galla, H.J. Barrier function of porcine choroid plexus 
epithelial cells is modulated by cAMP-dependent pathways in vitro. Brain Res 853, 
115-24 (2000). 
161. Moy, A.B. et al. Histamine alters endothelial barrier function at cell-cell and cell-
matrix sites. Am J Physiol Lung Cell Mol Physiol 278, L888-98 (2000). 
162. van Nieuw Amerongen, G.P. et al. Involvement of Rho kinase in endothelial barrier 
maintenance. Arterioscler Thromb Vasc Biol 27, 2332-9 (2007). 
163. Bogatcheva, N.V. et al. The suppression of myosin light chain (MLC) 
phosphorylation during the response to lipopolysaccharide (LPS): beneficial or 
detrimental to endothelial barrier? J Cell Physiol 226, 3132-46 (2011). 
164. Lecuit, T. & Lenne, P.F. Cell surface mechanics and the control of cell shape, 
tissue patterns and morphogenesis. Nat Rev Mol Cell Biol 8, 633-44 (2007). 
165. Ivanov, A.I., Hunt, D., Utech, M., Nusrat, A. & Parkos, C.A. Differential roles for 
actin polymerization and a myosin II motor in assembly of the epithelial apical 
junctional complex. Mol Biol Cell 16, 2636-50 (2005). 
 
 
7 APPENDIX  
7  APPENDIX 102 
7.1 Publications 
7.1.1 Original publications 
Hornburger M.C., Mayer B.A., Leonhardt S., Willer E.A., Zahler S., Beyerle A., 
Rajalingam K., Vollmar A.M., Fürst R. A novel role for inhibitor of apoptosis proteins 
(IAPs) as regulators of endothelial barrier function by mediating RhoA activation. 
FASEB J. In revision. 
 
Hornburger M.C., Mayer B.A., Zahler S., Beyerle A., Wegener J., Vollmar A.M., Fürst R. 
A comperative study of in vitro methods analyzing endothelial barrier function –  
conventional macromolecular permeability measurement versus sophisticated impedance 
sensing. In preparation. 
7.1.2 Abstracts 
Hornburger M.C., Mayer B.A., Rehberg M., Krombach F., Vollmar A.M., Fürst R. Analysis 
of endothelial barrier function by macromolecular permeability measurement and 
impedance sensing – two sides of a story. IBCA 2011, August 10-12, Regensburg, 
Germany 
 
Hornburger M.C., Mayer B.A., Willer E.A., Leonhardt S., Vollmar A.M., Fürst R. More than 
just cell death regulators: inhibitor of apoptosis proteins (IAPs) as modulators of 
endothelial permeability. Interact 2012, March 29-30, Munich, Germany 
 
Hornburger M.C., Mayer B.A., Vollmar A.M., Wegener J., Fürst R. A comparative study of 
in vitro methods analyzing endothelial barrier function – conventional macromolecular 
permeability measurement versus sophisticated impedance sensing. DPhG Annual 
Meeting 2012, October 10-13, Greifswald, Germany 
 
Hornburger M.C., Mayer B.A., Oberoi T., Willer E.A., Leonhardt S., Vollmar A.M., 
Rajalingam K., Fürst R. Inhibitor of apoptosis proteins (IAPs) antagonists protect against 
thrombin-induced endothelial hyperpermeability by preventing RhoA activation. DGPT 
Annual Meeting 2013, March 5-7, Halle, Germany 
  
7  APPENDIX 103 
7.2 Acknowledgements 
Diese Arbeit wurde an der Ludwig-Maximilians-Universität München, Department 
Pharmazie, am Lehrstuhl für Pharmazeutische Biologie von Frau Professor Dr. Angelika 
Vollmar unter der Betreuung von Herrn Professor Dr. Robert Fürst angefertigt. Herr 
Professor Dr. Fürst hat zwischenzeitlich eine Berufung der Goethe-Universität Frankfurt 
angenommen, wo er den Lehrstuhl für Pharmazeutische Biologie übernahm. Ihnen 
möchte ich an allererster Stelle danken, dass sie mir die Möglichkeit in ihrer Gruppe zu 
promovieren gegeben haben. Vielen Dank für die hervorragende fachliche und 
persönliche Betreuung, die hilfreichen Ratschläge und Diskussionen, sowie die 
Bereitschaft, sich immer die nötige Zeit für die Mitarbeiter zu nehmen. Ganz besonders 
jedoch möchte ich mich bei beiden für die freie Wahl des Arbeitsplatzes nach dem Umzug 
der Gruppe von Herrn Professor Dr. Fürst nach Frankfurt bedanken! Das ist keine 
Selbstverständlichkeit und zeugt von ihrem großen persönlichen Einsatz für das Wohl 
ihrer Mitarbeiter.  
Ein recht herzliches Dankeschön geht an meine wissenschaftliche Mentorin, Frau Dr. 
Bettina Mayer, für ihre exzellente Vorarbeit auf dem Gebiet der Inhibitor of apoptosis 
proteins (IAPs) im Endothel, sowie die Einführung in den „wissenschaftlichen Alltag“ und 
ihre ständige Diskussionsbereitschaft zu vielfältigsten Themen. Vielen Dank auch an 
Frau Dr. Andrea Beyerle für ihre andauernden Anstrengungen bei der Verfassung der 
Manuskripte für die Original Publikationen, und darüber hinaus viel Erfolg beim weiteren 
Erforschen der IAPs. An dieser Stelle möchte ich auch vielmals Herrn Prof. Dr. Zahler für 
die zahlreichen Ratschläge und technischen Hilfestellungen danken. 
Den Mitgliedern meines Prüfungskomitees gilt mein aufrichtiger Dank für Ihre Zeit und 
Mühe: Prof. Dr. Christian Wahl-Schott, Prof. Dr. Franz Paintner, Prof. Dr. Franz Bracher 
und Prof. Dr. Wolfgang Friess. 
Des Weiteren möchte ich mich bei unseren Kollaborationspartner bedanken: Dr. Krishna 
Rajalingam und Tripat Oberoi vom Institute für Biochemie II, Goethe-Universität, Frankfurt 
für Ihre Experimente und die lebhaften Diskussionen auf dem Gebiet der RhoA-IAP 
Interaktion. Prof. Dr. Joe Wegener, Institut für Analytische Chemie und Biosensorik, 
Universität Regenburg, für seine Erläuterungen zur Impedanz-Messung und die 
Experimente mit dem ECIS® Gerät.  
7  APPENDIX 104 
Ein großes Dankeschön an alle aktuellen und ehemaligen Mitglieder des Arbeitskreis 
Vollmar für das super Arbeitsklima und die gute Zeit im und außerhalb des Labors. Ein 
besonderer Dank gilt den Kollegen die (beinahe) parallel ihre Arbeit begonnen haben und 
mit mir gemeinsam gewachsen sind: Verena, Lena, Sandra, Simone, Tini und Flo. 
Ebenfalls ein großes Danke den „Ehemaligen“ und Post-Docs, die mir immer gute 
Vorbilder waren: Elisabeth, Sebastian, Sabine, sowie Hanna, Simone und Karin. Für die 
tatkräftige Hilfe im Labor möchte ich mich bei Jana, Bianca, Kerstin, Rita und Frau 
Schnegg bedanken. 
Ein besonderer Dank geht an Dr. Martin Bubik, der mich mit großem Eifer beim 
Coverdesign beraten hat. 
Ein großes Merci meinem Bruder und den Freunden für die nötige Abwechslung zur 
Wissenschaft. *<:o) 
Ein riesen Dankeschön meiner Verlobten, Anja, dafür, dass sich selbst der Alltag wie 
Urlaub anfühlt. Ich freue mich sehr auf unsere gemeinsame Zukunft! 
Tiefste Dankbarkeit gilt meinen Eltern, die mir alles ermöglicht haben und mich seit dem 
allerersten Tage unterstützen. Ihr hättet es nicht besser machen können! 
 
 
